European Neuropsychopharmacology

The treatment of schizophrenia in the next decades
pp. 107-107(1)
Author: Kane J.

Animal models of anxiety and depression: from behavior to genomics
pp. 107-107(1)
Author: Hen R.

Mode of action of atypical antipsychotic drugs
pp. 107-109(3)
Author: Svensson T.H.

Pharmacoepidemiology of coprescription of antidepressants and antipsychotics
pp. 111-111(1)
Author: Rittmannsberger H.

Coprescription of antipsychotics and antidepressants: Why, when and how?
pp. 111-112(2)
Author: Fleischhacker W.W.

The clinical advantage of the comedication of atypical antipsychotics and antidepressants
pp. 112-112(1)
Author: Naber D.

Adverse effects of the comedication of neuroleptics and antidepressants
pp. 112-113(2)
Authors: Grohmann R.; Engel R.; Hippius H.; Ruther E.

Treatment of psychiatric symptoms in Parkinson's disease
pp. 113-114(2)
Authors: Hoglinger G.U.; Oertel W.H.

Psychiatric disorders in Multiple Sclerosis
pp. 114-115(2)
Author: Kumpfel T.

Treatment of psychiatric symptoms in epilepsy
pp. 115-116(2)
Authors: Kramer G.; Toygar A.

Treatment of psychiatric symptoms in amyotrophic lateral sclerosis (ALS)
pp. 116-117(2)
Author: Pongratz D.

Treatment of behavioral and psychiatric disorders in Alzheimer's disease
pp. 117-117(1)
Author: Wahlund L.-O.

Nicotine dependence: Concepts from animal experiments
pp. 118-118(1)
Author: Stolerman I.P.

Nicotine consumption in mental disorders: a clinical epidemiological perspective
pp. 119-119(1)
Authors: Wittchen H.-U.; Sonntag H.

Opioid involvement in smoking behavior
pp. 120-120(1)
Author: Tejwani G.A.

Treatment of nicotine dependency with bupropion
pp. 120-121(2)
Author: Tonnesen P.

The mode of action of neuropeptides and its relevance for brain diseases
pp. 121-122(2)
Authors: Hokfelt T.; Xu Z.-Q.; Sergeyev V.; Diez M.; Broberger C.; Holmberg K.; Ubink R.; Schott P.; Ogren S.-O.; Kahl U.; Bartfai T.; Lendahl U.; Hurd Y.; Petersson S.; Lavebratt K.; Johansen J.; Schalling M.; Koistinaho J.; Kahn K.; Games D.; DeArmond S.J.; Prusiner S.

NK-1 antagonists as antidepressants - clinical studies
pp. 122-123(2)
Author: Kramer M.

Opioids and social disturbances
pp. 123-124(2)
Author: Van Ree J.M.

Neuropeptides in animal models of anxiety
pp. 124-124(1)
Author: Landgraf R.

CCK and panic disorder
pp. 124-125(2)
Authors: Bradwejn J.; Koszycki D.

Body dysmorphic disorder: assessment and treatment with serotonergic drugs
pp. 125-126(2)
Authors: Hollander E.; Twersky R.

The importance of the serotonergic system in fibromyalgia syndrome
pp. 126-127(2)
Authors: Schwarz M.J.; Bondy B.; Spaeth M.; Offenbaecher M.; Ackenheil M.

SSRIs in the treatment of premenstrual dysphoric disorder. Nefazodone: An open trial
pp. 127-128(2)
Authors: Pallanti S.; Quercioli L.

New data on serotonergic medication in migraine
pp. 128-129(2)
Author: van den Brink A.M.

The criteria for evaluating response to antipsychotics in schizophrenia
pp. 129-130(2)
Author: Kane J.

The use of novel antipsychotics to improve response in schizophrenia: a naturalistic study in poor responders
pp. 130-131(2)
Authors: Altamura A.C.; Mundo E.; Bassetti R.; Sassella F.; Salvadori D.; Pioli M.R.; Caprioli C.; Bignotti S.; Tura G.B.

Use of typical and atypical antipsychotics in schizophrenia: pharmacological and clinical aspects
pp. 131-132(2)
Authors: Muller N.; Riedel M.; Schaub A.; Bondy B.; Moller H.-J.; Ackenheil M.

Recent advances of pharmacogenetics in psychiatry
pp. 132-132(1)
Author: Kerwin R.

The effects of olanzapine on neuroendocrine responses induced by the serotonin agonist m-chlorophenylpiperazine (m-CPP)
pp. 132-134(3)
Authors: Scheepers F.E.; Gispen de Wied C.C.; Kahn R.S.

How to measure addictive behaviour in animal experiments
pp. 134-135(2)
Author: Spanagel R.

Brain circuits involved in craving
pp. 135-136(2)
Authors: Nutt D.J.; Daglish M.; Weinstein A.; Lingford-Hughes A.

Ultra-rapid detoxification of opioid addicts
pp. 136-136(1)
Authors: Scherbaum N.; Heringhaus A.; Kienbaum P.; Nebe J.; Heppekausen K.; Gastpar M.

Methadone maintenance: the recommended dose
pp. 136-137(2)
Author: Strain E.C.

Experience with buprenorphine
pp. 137-138(2)
Authors: Fischer G.; Eder H.; Peternell A.; Topitz A.; Kraigher D.

Antidopaminergic effects of acute tyrosine depletion in healthy subjects and patients with mania
pp. 138-139(2)
Authors: McTavish S.F.B.; McPherson M.H.; Harmer C.J.; Clark L.; Sharp T.; Goodwin G.M.; Cowen P.J.

New anxiety disorder treatments based on novel neurobiology
pp. 139-140(2)
Author: Gorman J.M.

Treatment for Alzheimer's disease - where are we going?
pp. 140-141(2)
Author: Wilcock G.K.

The biochemistry and genetics of signal transduction in bipolar disorder
pp. 141-142(2)
Authors: Bondy B.; Zill P.; Baghai T.; Neumeier K.

No differences in inositol monophosphatase activity and GSK-3 immunoreactivity between bipolar patients and normal controls in postmortem brain
pp. 142-143(2)
Authors: Agam G.; Shaltiel G.; Kozlovsky N.

cAMP signalling system in the pharmacotherapy and pathophysiology of bipolar disorder
pp. 143-143(1)
Authors: Perez J.; Tardito D.; Racagni G.; Smeraldi E.; Mori S.; Zanardi R.

The diagnosis and treatment of rapidly cycling bipolar disorder
pp. 144-144(1)
Author: Maj M.

New potential targets in the treatment of bipolar disorder: Animal models and neuropeptides
pp. 144-145(2)
Authors: Mathe A.A.; Jimenez Vasques P.A.; Gruber S.H.M.; Angelucci F.; Husum H.

Acute pharmacotherapy of depression in old age: A systematic analysis focussing on numbers needed to treat
pp. 145-146(2)
Authors: Katona C.; Livingston G.

The pharmacological management of psychotic behaviour in the elderly
pp. 146-147(2)
Author: McKeith I.G.

The use of typical and atypical antipsychotics in the treatment of elderly psychotic patients
pp. 147-147(1)
Author: Davidson M.

Parkinsonism and tardive dyskinesia in elderly patients
pp. 147-148(2)
Author: Gerlach J.

The psychopharmacological management of the early phase of Alzheimer's disorder
pp. 148-148(1)
Author: Muller-Spahn F.

Animal models of autism
pp. 148-149(2)
Authors: Gerrits M.A.F.M.; Van den Berg C.L.; Daenen E.W.P.M.; Wolterink G.; Van Ree J.M.

Molecular Genetics of autism: evidence for susceptibility loci
pp. 149-150(2)
Authors: Bailey A.; Maestrini E.; Paul A.; Monaco A.

Serotonin and autism
pp. 150-151(2)
Author: Poustka F.

Atypical neuroleptics and autism
pp. 151-152(2)
Author: Van Engeland H.

Do animal models of stroke predict clinical utility?
pp. 152-153(2)
Author: Vornov J.J.

Endogenous low molecular weight factors support extensive CNS axon growth
pp. 153-153(1)
Authors: Benowitz L.I.; Soni D.; Irwin N.

Functional repair of global and focal ischaemic brain damage by grafts of conditionally immortal neuroepithelial stem cells
pp. 153-154(2)
Authors: Gray J.A.; Sowinski P.; Modo M.; Stroemer P.; Veizovic T.; Tang E.; Watson W.P.; French S.J.; Chadwick A.; Mora A.; Rashid T.; McNally K.; Dawe G.; Patel S.; Sinden J.D.; Hodges H.

Neuroprotection and regeneration in spinal cord injury
pp. 154-155(2)
Authors: Privat A.; Gaviria M.; Gimenez M.; Ribotta Y.

The impact of bipolar disorders
pp. 155-156(2)
Author: Bourgeois M.L.

Comedication in bipolar disorders: a pharmacological view
pp. 156-157(2)
Authors: Ackenheil M.; Montane-Jaime K.

Treatment-algorithms of bipolar disorder
pp. 157-157(1)
Authors: Kasper S.; Zohar J.

The genetics of bipolar disorders: therapeutic implications
pp. 157-158(2)
Authors: Mendlewicz J.; Souery D.

The value of comedication in bipolar disorders
pp. 158-159(2)
Authors: Walden J.; Grunze H.

The use of knockout mice to study the role of 5-HT receptors in animal models of depression
pp. 159-159(1)
Author: Hen R.

Role of 5-HT_1B receptors in the activity of antidepressants in animal models
pp. 159-160(2)
Authors: Bourin M.; Gardier A.

The presynaptic function as target for antidepressants
pp. 160-160(1)
Authors: Popoli M.; Consogno E.; Nocera A.; Racagni G.

Clinical consequences of the control of NA and 5-HT release in antidepressant therapy
pp. 161-161(1)
Author: Blier P.

Patterns of response to serotonergic antidepressants
pp. 161-162(2)
Authors: Benkert O.; Szegedi A.; Muller M.J.

Psychosocial stress as a trigger for the adaptive modification of neuronal circuitry
pp. 162-163(2)
Author: Huther G.

Long term consequences in animals of a stress experience
pp. 163-163(1)
Authors: Piazza P.V.; Deroche V.; Rouge-Pont F.; Marinelli M.; Barrot M.; Le Moal M.

Maladaptation to stress in schizophrenia
pp. 163-164(2)
Author: Gispen-de Wied C.C.

Stress and depression: from vulnerability to treatment
pp. 164-165(2)
Authors: Newport D.J.; Nemeroff C.B.

The Munich vulnerability study on affective disorders: HPA system changes as risk factors
pp. 165-166(2)
Author: Modell S.

Targeted mutation of benzodiazepine receptors: new insights into structure and function
pp. 166-167(2)
Author: Mohler H.

Partial agonist benzodiazepines: Clinical experiences
pp. 167-168(2)
Author: Kavoussi R.

Neuroimaging benzodiazepine receptors: effects of disease and drugs
pp. 168-168(1)
Author: Lingford-Hughes A.

Insights into the mechanisms of benzodiazepine dependence
pp. 169-169(1)
Authors: Doble A.; Martin I.

GAD: Current treatment and costs
pp. 170-171(2)
Authors: Lecrubier Y.; Weiller E.

Older antidepressant drugs for generalized anxiety disorder: developing the concept
pp. 171-172(2)
Authors: Rickels K.; Rynn M.

Recent developments in the pharmaco-therapy of generalized anxiety disorder
pp. 172-172(1)
Authors: Den Boer J.A.; Bosker F.J.; Cremers T.I.F.H.; Westerink B.H.C.

Do the benzodiazepines still have a role in the treatment of GAD?
pp. 173-173(1)
Author: Lader M.

Can we model GAD experimentally in volunteers?
pp. 174-174(1)
Authors: Szabadi E.; Bradshaw C.M.

Neuronal nicotinic receptors in neurodegenerative disorders
pp. 174-175(2)
Author: Nordberg A.

Nicotinic receptors in Alzheimer's disease
pp. 175-176(2)
Author: Wevers A.

Nicotinic receptors and neurotrophic factors
pp. 176-177(2)
Authors: Belluardo N.; Mudo G.; Blum M.; Fuxe K.

Subtype selective nicotine agonists
pp. 177-178(2)
Author: Lloyd K.

Nicotinic treatment of degenerative neuropsychiatric disorders
pp. 178-179(2)
Authors: Newhouse P.A.; Kelton M.; Potter A.; Kahn H.; Corwin J.

fMRI in normal functioning and psychiatric disorders
pp. 179-180(2)
Author: Gabrieli J.D.E.

Beyond phrenology: using functional MRI to study brain dynamics
pp. 180-180(1)
Author: Berns G.S.

Glucocorticoids & cognition in depression
pp. 180-180(1)
Authors: Schatzberg A.F.; DeBattista C.; Posener J.

Cognition, antipsychotic drugs, and treatment response
pp. 180-181(2)
Author: Meltzer H.

Receptors and ligands
pp. 181-182(2)
Author: Pertwee R.G.

CB₁ receptor mediated effects on brain neurotransmitter systems
pp. 182-183(2)
Authors: Van Vliet B.J.; Nievelstein H.N.M.W.; Long S.K.; Kruse C.G.

Behavioral effects of cannabinoid agonists
pp. 183-184(2)
Authors: Lichtman A.H.; Martin B.R.

Synthetic cannabinoids, potential therapeutic agents of the central nervous system
pp. 184-185(2)
Author: Pop E.

The epidemiology, natural history, and pharmacoeconomics, of social anxiety and PTSD
pp. 185-186(2)
Author: Kessler R.C.

Diagnostic dilemmas in social anxiety disorder and posttraumatic stress
pp. 186-187(2)
Author: Stein D.J.

Comprehensive treatment of social anxiety disorder
pp. 187-189(3)
Author: Baldwin D.

Neurobiology of anxiety disorders: Focus on neuroimaging
pp. 189-189(1)
Author: Westenberg H.G.M.

Treating PTSD - SSRI's and beyond
pp. 190-190(1)
Authors: Zohar J.; Sasson Y.; Amital D.

New avenues in the treatment of dementia
pp. 191-191(1)
Authors: Winblad B.; Nordberg A.

Neuronal nicotinic subtype selective agonists in treatment of dementia
pp. 191-192(2)
Author: Kem W.R.

Cholinesterase inhibitors in the treatment of dementia
pp. 192-193(2)
Author: Anand R.

The role of atypical antipsychotics in managing dementia
pp. 193-194(2)
Author: De Deyn P.P.

The use of oestrogen in the prevention and treatment of Alzheimer's disease
pp. 194-195(2)
Author: Maki P.M.

Functional MRI: current use and future prospects in human and animal research
pp. 195-196(2)
Author: Morris P.G.

Behavioural challenges and functional brain imaging in anxiety disorders
pp. 196-197(2)
Author: Malizia A.L.

Functional neuroanatomy of schizophrenia
pp. 197-197(1)
Author: McGuire P.K.

Neuroreceptor imaging in depression
pp. 197-198(2)
Authors: Grasby P.; Sargent P.; Rabiner E.; Messa C.; Bench C.; Cowen P.

SPECT imaging of drug effects in humans
pp. 198-199(2)
Author: Schlaepfer T.E.

Molecular pharmacology of the histamine H₃ receptor
pp. 199-199(1)
Authors: Schwartz J.-C.; Morisset S.; Rouleau A.; Gbahou F.; Ligneau X.; Tardivel-Lacombe J.; Heron A.; Arrang J.M.

Modulation of neurotransmitter release via histamine H₃ receptors
pp. 199-200(2)
Authors: Schlicker E.; Kathmann M.

The histamine H₃ receptor and its relation to normal and altered behavior
pp. 200-201(2)
Author: Monti J.M.

What are the optimal tests for determining enhanced cognitive function in humans?
pp. 201-202(2)
Author: Wesnes K.A.

Cognitive and sleep effects of antihistamines: Human studies
pp. 202-203(2)
Authors: Alford C.; Hindmarch I.; Stanley N.; Yorke L.

Mood spectrum and residual symptoms
pp. 203-203(1)
Author: Cassano G.B.

New data on augmentation strategies in depression
pp. 203-204(2)
Author: Artigas F.

The use of thyroid hormones as augmentation strategy in depression
pp. 204-205(2)
Authors: Bauer M.; Berghoefer A.; Bschor T.; Baumgartner A.

Management of resistant depression
pp. 205-206(2)
Author: Souery D.

Serotonin, suicide and impulsiveness
pp. 206-207(2)
Authors: Åsberg M.; Forslund K.

Nosologia and treatment of impulse disturbances
pp. 207-207(1)
Author: Sasz H.

Dimensions vs categories in OCD-related disorders
pp. 207-208(2)
Author: Marazziti D.

Clinical, biological and treatment characteristics of intermittent explosive disorder
pp. 208-209(2)
Author: Coccaro E.F.

NMDA receptor hypofunction and animal models of schizophrenia
pp. 209-210(2)
Authors: Jentsch J.D.; Grace A.A.; Roth R.H.

Glutamate receptors in control of dopaminergic systems
pp. 210-211(2)
Author: Svensson T.H.

PCP-site ligands and the glutamate hypothesis of schizophrenia
pp. 211-211(1)
Authors: Kornhuber J.; Bleich S.; Wiltfang J.

NMDA-sensitive glutamate antagonism: A human model for psychosis
pp. 211-211(1)
Authors: Lahti A.C.; Holcomb H.H.; Gao X.M.; Tamminga C.A.

Efficacy and safety of glycine site agonists of the N-methyl-D-aspartate receptor in schizophrenia treatment
pp. 212-212(1)
Author: Heresco-Levy U.

Molecular modeling of the GABA_B receptor subdomains: Two putative binding sites in allosteric interaction?
pp. 212-213(2)
Authors: Bernard P.; Guedin D.; Hibert M.

Allosteric properties of G protein-coupled receptors - The example of muscarinic acetylcholine receptors
pp. 213-214(2)
Authors: Birdsall N.J.M.; Lazareno S.

5-HT-moduline, an endogenous allosteric modulator of 5-HT1B receptor
pp. 214-214(1)
Authors: Fillion G.; Massot O.; Grimaldi B.

Allosteric modulation of adenosine receptors
pp. 214-215(2)
Authors: Ijzerman A.P.; Van der Klein P.A.M.; De Ligt R.A.F.; Kourounakis A.P.

Excess TPH 17 779C allele in surviving cotwins of monozygotic twin suicide victims
pp. 217-217(1)
Authors: Roy A.; Rylander G.; Forslund K.; Asberg M.; Mazzanti C.; Goldman D.; Nielsen D.

The differential reinforcement of low-rate (DRL) 72 model for characterization of antidepressant agents: Noradrenaline, but not serotonin or dopamine, uptake inhibitors mimic the actions of imipramine
pp. 217-217(1)
Authors: Dekeyne A.; Adhumeau-Auclair A.; Girardon S.; Millan M.J.

Discriminative stimulus properties of the selective serotonin uptake inhibitor, citalopram, in rats: Generalization with duloxetine, venlafaxine and clomipramine, but blockade by mirtazapine and mianserin
pp. 217-218(2)
Authors: Dekeyne A.; Iob L.; Millan M.J.

Using cluster analysis to identify subtypes within a study population following treatment with a new pentapeptide antidepressant (statistical and clinical aspects)
pp. 218-219(2)
Authors: Feighner J.P.; Sverdlov L.; Noble J.F.; Nicolau G.; Ehrensing R.; Kastin A.

Bipolar II chronic depression: effects of age at onset on clinical features
pp. 219-219(1)
Author: Benazzi F.

Prevalence of depressive mixed states in depressed outpatients
pp. 219-220(2)
Author: Benazzi F.

Evaluation of incidence, prevalence and time-course of depression after acute myocardial infarction
pp. 220-220(1)
Authors: Sathananthan K.; Canepa-Anson R.; Hamlet S.

Occurrence of mirtazapine-induced delirium in organic brain disorder - Three case reports
pp. 220-220(1)
Authors: Bailer U.; Fischer P.; Kufferle B.; Stastny J.; Kasper S.

Fluoxetine in panic disorder: a randomized, placebo-controlled study
pp. 220-221(2)
Authors: Michelson D.; Allgulander C.; Bjorling G.; Dantendorfer K.; Dejanovic S.; Knezevic A.; Maierhofer D.; Micev V.; Paunovic V.R.; Skoglund L.; Timotijevic I.; Sarkar N.; Pemberton S.C.

Sexual functional during acute and continuation therapy with fluoxetine: a prospective assessment
pp. 221-221(1)
Authors: Michelson D.; Schmidt M.E.

Gender differences in the antidepressive effect? A double blind trial of fluoxetine and maprotiline in the treatment of major depression
pp. 221-221(1)
Authors: Martenyi F.; Dossenbach M.; Mraz K.; Metcalfe S.

Intracerebroventricular antisense to inositol monophosphatase 1 reduces the enzyme activity but does not affect Li-sensitive behavior
pp. 221-222(2)
Authors: Shaltiel G.; Shamir A.; Belmaker R.H.; Agam G.

The relevance of serum carbamazepine levels in affective and schizoaffective disorders
pp. 222-222(1)
Authors: Degner D.; Schink C.; Bleich S.; Kornhuber J.; Ruther E.

Tardive dyskinesia exacerbating with mania: a case report
pp. 222-223(2)
Authors: Esel E.; Turan M.T.; Basturk M.; Kartalci S.; Oguz A.; Gonul A.S.

Effects of the 5-HT2C agonist, RO 60-0175, on the antidepressant drug action in the mouse forced swimming test
pp. 223-223(1)
Authors: Bourin M.; Clenet F.

Comparison of the effects of the monoamines oxidase inhibitor tranylcypromine and its 4-fluoro analogue in the forced swimming test in mice
pp. 223-223(1)
Authors: Bourin M.; Hascoet M.; Colombel M.C.; Coutts R.T.; Baker G.B.

Physical signs in psychiatry - a step towards evidence based medicine
pp. 223-224(2)
Authors: Gupta R.K.; Kasper S.

Imidazoline receptors: potential markers for depression and targets of antidepressant drug development
pp. 224-224(1)
Authors: Halaris A.; Piletz J.

The modulatory effects of hypericum (St. John's wort) and its chemical constituent hyperforin in passive avoidance in the rat: comparative studies with paroxetine and imipramine
pp. 224-225(2)
Authors: Misane I.; Ogren S.O.

Sertraline versus imipramine in non-melancholic depression
pp. 225-225(1)
Authors: Baca E.; Gonzalez de Chavez M.; Garcia-Toro M.; Perez-Arnau F.; Rivera A.; Penasa B.; Oliveros S.; Espejo J.; Porras-Chavarino A.; Lane R.

Antidepressant early response and remission of venlafaxine and fluoxetine in geriatric outpatients
pp. 225-226(2)
Authors: Schatzberg A.F.; Cantillon M.

Effects of reboxetine on HAM-D factors among depressed patients
pp. 226-226(1)
Authors: Ferguson J.; Mendels J.; Montgomery S.; Stahl S.; Schwartz G.

Efficacy of reboxetine in patients with severe major depression
pp. 226-226(1)
Authors: Montgomery S.; Stahl S.; Ferguson J.; Mendels J.; Schwartz G.

Premenstrual dysphoric disorder (PMDD) and work efficiency: response to fluoxetine in a randomized clinical trial
pp. 226-227(2)
Authors: Steiner M.; Trzepacz P.T.; Brown E.

The relative effectiveness of selective serotonin reuptake inhibitors and tricyclic antidepressants in reducing worker absenteeism
pp. 227-227(1)
Authors: Neslusan C.A.; Treglia M.

Predictors of death in bipolar disorder
pp. 227-227(1)
Authors: Tsai S.-Y.M.; Kuo C.-J.; Lee H.-C.; Chen C.-C.; Su K.P.

Effects of psychotropic agents on plasma levels of soluble interleukin-2 and interleukin-6 receptors in bipolar mania
pp. 227-228(2)
Authors: Lee H.C.; Tsai S.Y.; Leu S.J.; Yang Y.Y.; Chen K.P.

Depression, disability and service use in primary health care in six countries
pp. 228-228(1)
Authors: Herrman H.; Diehr P.; Fleck M.; Simon G.; Patrick D.; The LIDO Group

Mirtazapine versus amitriptyline in treatment of major depressive disorder
pp. 228-229(2)
Authors: Turan M.; Askin R.; Telcioglu M.; Cilli A.S.

Effortful and effortless deficits of cognitive processing in clinical depression
pp. 229-229(1)
Authors: Politis A.; Oulis P.; Hatzimanolis I.; Rigas G.; Christodoulou G.N.; Stefanis C.N.

The treatment of depression in the psychiatric practice in Switzerland: a survey study
pp. 229-230(2)
Authors: Delini-Stula A.; Deutschmann R.; Schneider M.; Holsboer-Trachsler E.

Social adjustment of patients with depression is improved with effective treatment: a venlafaxine study in general practice
pp. 230-230(1)
Authors: Lecrubier Y.; Mahe V.; Hackett D.; Haudiquet V.

Differential efficacy of venlafaxine ER and fluoxetine in patients with major depressive disorder and co-morbid generalized anxiety disorder
pp. 230-231(2)
Authors: Silverstone P.H.; Hackett D.; Salinas E.O.

Coadministration therapy with reboxetine and serotonin specific reuptake inhibitors in twenty-four patients with major depression
pp. 231-231(1)
Authors: Hawley C.J.; Sivakumaran T.; Ochocki M.; Bevan J.; Hertfordshire Neuroscience Research Group

Repetitive transcranial magnetic stimulation in major depression - The impact of stimulation intensity on therapeutic efficacy
pp. 231-231(1)
Authors: Zwanzger P.; Thoma H.; Mikhaiel P.; Ella R.; Hampel H.; Moller H.-J.; Padberg F.

Association of angiotensin I converting enzyme gene I/D polymorphism with therapeutic outcome in depressive disorder
pp. 232-232(1)
Authors: Baghai T.C.; Minov C.; Schule C.; Zwanzger P.; Schwarz M.J.; De Jonge S.; Rupprecht R.; Bondy B.

Hypothalamic-pituitary-adrenal (HPA) axis activity and response to transcranial magnetic stimulation in responders and nonresponders to sleep deprivation
pp. 232-232(1)
Authors: Schule C.; Padberg F.; Baghai T.; Zwanzger P.; Minov C.; Moller H.J.; Rupprecht R.

Angiotensin-converting-enzyme gene I/D polymorphism is associated with hyperactivity of the HPA system in depressive patients
pp. 233-233(1)
Authors: Minov C.; Baghai T.C.; Schule C.; Zwanzger P.; Schwarz M.J.; De Jonge S.; Bondy B.; Rupprecht R.

Depression in general practice: Symptoms recognised and treated
pp. 233-233(1)
Authors: Rasmussen J.G.C.; Kosky N.J.

Coordinate manifestation in corticotropin-releasing hormone (CRH) and monoaminergic systems after chronic variable stress in the rat brain
pp. 234-234(1)
Authors: Nagashima H.; Misonoh A.; Fujii S.; Hasegawa H.; Sasuga Y.; Osada K.; Asakura M.

Baseline characteristics of major depressive disorder patients in clinical trials: Is there a transatlantic difference?
pp. 234-234(1)
Authors: Niklson I.A.; Reimitz P.-E.

Cardiovascular risk factors and lithium in bipolar disorder
pp. 235-235(1)
Authors: Klumpers U.M.H.; Tulen J.H.M.; Loonen A.J.M.; Boom K.; Janssen F.M.G.; Pepplinkhuizen L.

Autonomic neurocardiac regulation in major depressive disorder
pp. 235-236(2)
Authors: Volkers A.C.; Tulen J.H.M.; Van den Broek W.W.; Bruijn J.A.; Passchier J.; Pepplinkhuizen L.

Weight gain associated with valproate vs. lamotrigine monotherapy in patients with epilepsy: A randomized, double-blind comparative clinical trial
pp. 236-236(1)
Authors: Biton V.; Mirza W.; Montouris G.; Earl N.; Vuong A.; Hammer A.; Barrett P.

Anxiolysis associated with antidepressant response to bupropion sustained release or sertraline
pp. 236-236(1)
Authors: Rush A.J.; Trivedi M.H.; Batey S.R.; Donahue R.M.J.; Carmody T.J.; Houser T.L.; Ascher J.A.; Bolden-Watson C.; Evoniuk G.; Metz A.

A one-year open-label study of the safety and efficacy of lamotrigine in the treatment of bipolar depression
pp. 236-237(2)
Authors: Bentley B.; Ascher J.; Earl N.; Monaghan E.; Evoniuk G.; Batey S.; Dempsey G.; El-Mallakh R.; DeBus J.; Cohen A.

A one-year continuation study of lamotrigine treatment in bipolar depression
pp. 237-237(1)
Authors: Huffman R.; Ascher J.; Earl N.; Monaghan E.; Womble G.; Mitchell P.; Cookson J.; Vanier B.; Dinan T.; Calabrese J.

Mood stabilisation with lamotrigine in rapid cycling bipolar disorder
pp. 237-238(2)
Authors: Earl N.; Greene P.; Ascher J.; Fouche N.; Chang C.; Evoniuk G.; Swann A.; Pope S.; Ketter T.; McElroy S.; Post R.; Zajecka J.; Altshuler L.; Apter J.; West S.; Risch C.; Khan A.

Mood stabilisation with lamotrigine in rapid cycling bipolar disorder: A double-blind placebo-controlled study
pp. 238-238(1)
Authors: Kusumakar V.; Greene P.; Earl N.; Ascher J.; Monaghan E.; Smoot T.; Fouche N.; Bowden C.; Calabrese J.; Post R.; Sachs G.; Suppes P.; Gyulai L.; Young T.; Rapaport M.

Assessing the validity of a model of cost-effectiveness of fluvoxamine in depression in France using observational data on treatment patterns
pp. 238-238(1)
Authors: Piercy J.; Nuijten M.J.C.

CYP2D6 phenotype and genotype analysis in polymedicated depressed inpatients
pp. 238-239(2)
Authors: Haffen E.; Paintaud G.; Vandel P.; Broly F.; Vandel S.; Nezelof S.; Bonin B.; Kantelip J.P.; Bizouard P.; Bechtel P.R.; Sechter D.

Economic aspects of nefazodone, CBASP, and their combination for the treatment of chronic depression
pp. 239-239(1)
Authors: Russell J.M.; Crown W.H.; Arnow B.A.; Blalock J.A.; Dunner D.L.; Hirschfeld R.M.A.; Kocsis J.H.; Koran L.M.; Kornstein S.G.; Manber R.; Markowitz J.C.; Rush A.J.; Thase M.E.; Trivedi M.H.; Berndt E.; Finkelstein S.N.; Borian F.E.

Risperidone as an adjunctive treatment in mixed mania
pp. 239-239(1)
Authors: Vieta E.; Corbella B.; Benabarre A.; Reinares M.; Martinez G.; Fernandez A.

Risperidone therapy in bipolar disorder: Results from a 6-month open-label study in Spain
pp. 240-240(1)
Authors: Vieta E.; Benabarre A.; Martinez G.; Fernandez A.; Gasto C.; The Spanish Group for the Study of Risperidone in Affective Disorders

Efficacy and tolerability of risperidone versus placebo in combination with lithium or valproate in acute mania
pp. 240-240(1)
Authors: Sachs G.; Ghaemi S.N.

Bipolar disorder: A cyclical condition requiring a multiphasic approach to management
pp. 240-241(2)
Author: Kusumakar V.

Efficacy of venlafaxine in depressed patients after failure with prior antidepressant treatment
pp. 241-241(1)
Authors: De Clercq M.; Mignon A.; The 600A-GAP-BE Study Group

Efficacy of venlafaxine in depressed patients after switching from prior SSRI treatment
pp. 241-241(1)
Authors: Reynaert C.; Janne P.; Zdanowicz N.; Mignon A.; The 600A-GAP-BE Study Group

Symptom relief obtained with Venlafaxine versus fluoxetine in depressed patients with concomitant anxiety
pp. 242-242(1)
Authors: De Nayer A.; De Clercq M.; Mignon A.

A naturalistic study of reboxetine in the Spanish psychiatric practice
pp. 242-242(1)
Authors: Bobes J.; De la Gandara J.; Such P.

Predictors of hypomania occurring during the antidepressant treatment
pp. 242-243(2)
Authors: Zivanovic O.; Borisev L.; Borisev V.; Paunovic V.R.

Short term and long term effects of venlafaxine and trimipramine on cognitive psychomotor performance in patients with major depression
pp. 243-243(1)
Authors: Hemmeter U.; Bruderlin U.; Hatzinger M.; Annen B.; Holsboer-Trachsler E.

Sleep EEG measures in major depression: Predictive markers for long-term course
pp. 243-244(2)
Authors: Hatzinger M.; Hemmeter U.; Baumann K.; Annen B.; Holsboer-Trachsler E.

Benefits and risks of antidepressants in hospital use
pp. 244-244(1)
Authors: Reyntens J.; De Boever W.; Wirix H.; De Bruycker A.; Bilo R.; Van Ganse E.

Reboxetine does not influence parasympathetic mediated autonomic neurocardiac regulation (ANR)
pp. 244-245(2)
Authors: Agelink M.W.; Lemmer W.

Reboxetine vs desipramine and imipramine: An overview of tolerability
pp. 245-245(1)
Author: Versiani M.

Reboxetine, a novel selective NRI, in the treatment of panic disorder
pp. 245-246(2)
Author: Versiani M.

Topiramate shows efficacy against mania in an open study with an on-off-on protocol
pp. 246-246(1)
Authors: Grunze H.; Normann C.; Schaefer M.; Schloesser S.; Marcuse A.; Walden J.

Risperidone treatment for acute mania: assessment of tolerability
pp. 246-246(1)
Authors: Bowden C.; Sachs G.

Depression during mania: treatment response to olanzapine or placebo
pp. 246-247(2)
Authors: Baker R.W.; Tohen M.; Risser R.C.; Stauffer V.L.; Breier A.; Tollefson G.D.

Olanzapine in the treatment of juvenile bipolar disorder
pp. 247-247(1)
Authors: Frazier J.A.; Tohen M.; Biederman J.; Jacobs T.; Toma V.; Feldman P.

Impact of olanzapine added to lithium or valproate on the quality of life of patients with bipolar disorder
pp. 247-247(1)
Authors: Namjoshi M.; Rajamannar G.; Risser R.; Tohen M.; Breier A.

Effects of tryptophan depletion and repetitive transcranial magnetic stimulation on human sleep
pp. 247-248(2)
Authors: Hajak G.; Cohrs S.; Wortelboer U.; Lange K.; Rodenbeck A.

The influence of antidepressive treatment on EEG in depressive patients
pp. 248-248(1)
Authors: Jernajczyk W.; Wierzbicka A.; Antczak J.; Czasak K.; Trojecka A.

Doxepin in the treatment of primary insomnia - A placebo-controlled, double-blind, polysomnographic study
pp. 248-249(2)
Authors: Hajak G.; Rodenbeck A.; Voderholzer U.; Riemann D.; Cohrs S.; Hohagen F.; Berger M.; Ruther E.

The SSRI/5-HT_2A antagonist YM992 produces inverse effects compared to SSRIs on the firing activity of noradrenergic neurons
pp. 249-249(1)
Authors: Szabo S.T.; Blier P.

Multicenter double-blind randomized parallel-group clinical trial of effectiveness of the combination clomipramine (150 mg/day) plus lithium carbonate (750 mg/day) versus clomipramine (150 mg/day) plus placebo in the treatment of unipolar major depression
pp. 249-249(1)
Authors: Januel D.; Poirier M.-F.; D'Alche-Biree F.; Dib M.; Olie J.-P.

Outcome predictors in bipolar disorder: a catamnestic study
pp. 249-250(2)
Authors: Amore M.; Casagrande C.; Melucci V.; Torroni A.; Croci R.; Beverini E.; Ferrari G.

The effects of citalopram metabolites on dog heart in vitro: an electrophysiological study
pp. 250-250(1)
Authors: Faivre J.F.; Forest C.F.; Tulloch I.; Bril A.

Efficacy and tolerability of risperidone as combination therapy in bipolar mania: results from a randomised, double-blind study (RIS-INT-46)
pp. 250-251(2)
Author: Yatham L.N.

Regulation of 5-HT_1A and 5-HT₄ receptors in rat hippocampus by antidepressants and corticosterone
pp. 251-251(1)
Authors: Bijak M.; Zahorodna A.; Tokarski K.

Effectiveness of tramadol as antidepressant in the learned-helplessness model of depression
pp. 251-252(2)
Authors: Mico J.A.; Rojas-Corrales M.O.; Moreno-Brea M.R.; Ortega-Alvaro A.; Roca-Vinardell A.; Gilbert-Rahola J.

Effects of mirtazapine, paroxetine and their combination: a double-blind study in major depression
pp. 252-252(1)
Authors: Debonnel G.; Gobbi G.; Turcotte J.; Boucher N.; Hebert C.; De Montigny C.; Blier P.

Tianeptine versus dosulepine in the treatment of acute depressive disorders. A controlled study
pp. 252-253(2)
Authors: Svestka J.; Synek O.

Penetration of antidepressant drug into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1ab P-glycoprotein disruption
pp. 253-253(1)
Authors: Uhr M.; Boll E.; Steckler T.; Yassouridis A.; Holsboer F.

Evidence for an association between a G-protein-3-gene variant with depression and response to antidepressant treatment
pp. 253-253(1)
Authors: Zill P.; Baghai T.; Zwanzger P.; Schule C.; Minov C.; Rupprecht R.; Riedel M.; Neumeier K.; Bondy B.

Effect of amitriptyline treatment on the mRNA levels of the transcription factors c-jun, c-fos and zif 268 on immortalized lymphocytes of depressed patients
pp. 253-254(2)
Authors: Zill P.; Baghai T.; De Jonge S.; Neumeier K.; Bondy B.

Differential effects of tricyclic antidepressants and paroxetine on gait performance in depression
pp. 254-254(1)
Authors: Lemke M.R.; Wendorff T.

The incidence and duration of missed doses during SSRI treatment
pp. 254-255(2)
Authors: Meijer W.; Bouvy M.; Heerdink E.R.; Urquhart J.; Leufkens H.G.M.

The synergistic effect of amantadine and antidepressant drugs in the forced swimming test in rats
pp. 255-255(1)
Authors: Maj J.; Rogoz Z.

Cardiologic relations of citalopram drop infusion therapy
pp. 255-255(1)
Authors: Kovacs G.; Kelemen E.; Kiraly L.

The effect of antidepressant drugs on transcriptional activity of dopamine D₂ receptor gene promoter in the NB41A3 cells - In vitro study
pp. 255-256(2)
Authors: Goralska M.; Kucharska A.; Sobota R.; Dziedzicka-Wasylewska M.

Correlation between alpha2-adrenoreceptors and symptom severity in major depression
pp. 256-256(1)
Authors: Marazziti D.; Baroni S.; Masala I.; Di Nasso E.; Giannaccini G.; Cassano G.B.

Cortisol promotes non-REM sleep in patients with major depression
pp. 256-256(1)
Authors: Schmid D.A.; Brunner H.; Holsboer F.; Friess E.

Five-year maintenance treatment with citalopram in recurrent major depressive disorder
pp. 256-257(2)
Authors: Vavrusova L.; Konikova M.; Benedekova Z.

Effects of reboxetine and paroxetine compared to placebo on cognitive processes in healthy volunteers
pp. 257-257(1)
Authors: Straube E.R.; Steil R.; Kriese B.; Kimmel M.; Sauer H.; Schuler P.; Volz H.-P.

Serum cholesterol level and suicidal thoughts
pp. 257-257(1)
Authors: Kecskes I.; Rihmer Z.; Belso N.; Pestality P.; Kiss K.

Pharmacological profile of newly synthesized oxotechnitium ligands for the in vivo imaging of brain 5-HT_1A receptors
pp. 257-258(2)
Authors: Drossopoulou G.; Dalla C.; Antoniou K.; Papagianopoulou D.; Pirmettis I.; Maina T.H.; Papadopoulos M.; Chiotellis E.; Papadopoulou-Daifotis Z.

Gender differences in the response to sertraline versus imipramine in non-melancholic depression
pp. 258-258(1)
Authors: Baca E.; Porras-Chavarino A.

Electroconvulsive therapy in treatment resistant bipolar disorder - Case reports
pp. 258-258(1)
Authors: Soares M.B.M.; Moreno R.A.; Moreno D.H.

Association study of affective disorders with genetic polymorphisms of monoamine oxidases
pp. 259-259(1)
Authors: Muller-Siecheneder F.; Rujescu D.; Szegedi A.; Anghelescu I.; Giegling I.; Gietl A.; Schafer M.; Moller H.-J.; Dahmen N.

Association study of suicidal behavior and affective disorders with a genetic polymorphism in ABCG1, a positional candidate on chromosome 21q22.3
pp. 259-260(2)
Authors: Rujescu D.; Szegedi A.; Anghelescu I.; Giegling I.; Gietl A.; Schafer M.; Muller-Siecheneder F.; Bondy B.; Moller H.-J.; Dahmen N.

Antidepressant associated suicidality
pp. 260-260(1)
Author: Healy D.

Memory assessment 25 years after ECT treatment
pp. 260-260(1)
Authors: Kohl C.; Gwiggner M.; Gurka P.; Bodner T.; Kemmler G.; Hinterhuber H.; Marksteiner J.

Sertraline and fluoxetine treatment of OCD: a 6-month, double-blind, parallel study
pp. 260-260(1)
Authors: Bergeron R.; Hadrava V.; Ravindran R.

Effects of pharmacotherapy to depression in the period of adolescence
pp. 261-261(1)
Authors: Munjiza M.; Ljubomirovic N.; Vidojevic P.

Better than well on antidepressants
pp. 261-261(1)
Authors: Healy H.; Cattell D.; Tranter R.; Jaffar K.; Healy D.

Simultaneous use of sertraline and hormonal replacement therapy (HRT) in women with major depression during the menopausal period
pp. 261-262(2)
Authors: Krogulski S.; Lipinska-Szalek A.; Rabe-Jablonska J.

Theobromine and tryptophan alone or in association lack potential antidepressant-like effects whereas chronic paroxetine is effective in a genetic mouse model of depressive disorder
pp. 262-262(1)
Authors: El Yacoubi M.; Costentin J.; Vaugeois J.-M.

Depression in the psychiatric practice in Switzerland: a survey study
pp. 262-263(2)
Authors: Holsboer-Trachsler E.; Deutschmann R.; Delini-Stula A.

Sexual dysfunctions in depressed outpatients during long-term therapy with moclobemide and SSRIs - The results of an open, prospective, observational study
pp. 263-263(1)
Authors: Fauchere P.-A.; Antonioli D.; Mullor R.; Bischoff S.; Delini-Stula A.

Onset of action of mirtazapine on depression related symptoms: factor analysis of pooled data mirtazapine versus SSRIs
pp. 263-263(1)
Authors: Schutte A.J.; Van Hensbeek I.; Reimitz P.

Donepezil in therapy-refractory depression
pp. 264-264(1)
Authors: Kemmerich M.; Quartz P.; Berger F.M.; Kuthmann A.

Fluoxetine and amitriptyline: differential cognitive effects in depressed patients
pp. 264-264(1)
Authors: Ivkovic M.; Jasovic-Gasic M.; Maric N.; Paunovic V.R.

Onset of action of mirtazapine on anxiety symptoms related to depression
pp. 264-265(2)
Authors: Van Hensbeek I.; Schutte A.J.; Reimitz P.

Mirtazapine has similar long-term efficacy and tolerability to citalopram and faster onset of action in the treatment of major depression
pp. 265-265(1)
Authors: Leinonen E.; Skarstein J.; Behnke K.; Ångren H.; Schutte A.J.; The Nordic Antidepressant Study Group

Mirtazapine and the onset of antidepressant action: survival function analysis-response
pp. 265-265(1)
Authors: Nierenberg A.A.; Kremer C.; Reimitz P.

Mirtazapine in relapse prevention: a double-blind placebo-controlled study in depressed outpatients
pp. 265-266(2)
Authors: Thase M.E.; Nierenberg A.A.; Keller M.B.

Mirtazapine and onset of action of antidepressant activity
pp. 266-266(1)
Authors: Montgomery S.; Schutte A.J.; Reimitz P.

Efficacy and tolerability of mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholia
pp. 266-266(1)
Authors: Guelfi J.D.; Van Hensbeek I.; Ansseau M.; Korsgaard S.; Timmerman L.

Comparison of antidepressant-like activity of Lu 28-179, a selective ₂ ligand, citalopram and imipramine in a chronic mild stress model of depression in rats
pp. 266-267(2)
Authors: Papp M.; Sanchez C.

Choice of method and lethality in suicidal behaviour - overdoses during a 14 years period in Baranya region, Hungary
pp. 267-267(1)
Authors: Fekete S.; Osvath P.; Jegessy A.

Morning and evening plasma melatonin and dexamethasone suppression test in non-seasonal major depressive patients from Northern Greece (latitude 40-41.5^o)
pp. 267-268(2)
Authors: Fountoulakis K.N.; Karamouzis M.; Iacovides A.; Nimatoudis J.; Diakogiannis J.; Kaprinis G.; Demitriadou A.; Bech P.

Sleep disturbance in affective disorders: relationship to family history
pp. 268-268(1)
Authors: Papadimitriou G.N.; Dikeos D.G.; Daskalopoulou E.G.; Soldatos C.R.

Chronobiological lithium effects in rats with lesion of suprachiasmatic nucleus
pp. 268-268(1)
Authors: Zamoshchina T.; Meleshko M.

The new prolonged lithium compounds
pp. 269-269(1)
Authors: Zamoshchina T.; Isupov V.; Matveyenko A.

Antidepressant or immunomodulator induced regulation of cell signalling in brain and immune system
pp. 269-270(2)
Authors: Kovaru H.; Fiserova A.; Kovaru F.; Paclt I.; Lisa V.

Verbal memory deficits associated with unipolar affective disorder
pp. 270-270(1)
Authors: Totic S.; Marinkovic D.; Maric N.; Brankovic S.; Jasovic-Gasic M.; Paunovic V.R.

Interaction of tricyclic antidepressants with liposomes
pp. 270-270(1)
Author: Fisar Z.

Significance of the brain mineralocorticoid receptor in stress and stress-related mental disorders
pp. 271-271(1)
Authors: Gesing A.; Bilang-Bleuel A.; Droste S.; Linthorst A.C.E.; Reul J.M.H.M.

Acute and chronic treatment with the selective glucocorticoid receptor antagonists ORG 34850, ORG 34116 and ORG 34517 alters multiple parameters of the rat hypothalamic-pituitary-adrenocortical system
pp. 271-271(1)
Authors: Bachmann C.G.; Linthorst A.C.E.; Reul J.M.H.M.

The anxiolytic effect of the novel CRH₁ receptor antagonist R121919 depends on innate emotionality in rats
pp. 272-272(1)
Authors: Keck M.E.; Welt T.; Renner U.; Wigger A.; Landgraf R.; Holsboer F.

Effects of dexamethasone on various immunological parameters in patients with major depression
pp. 272-272(1)
Authors: Schuld A.; Kraus T.; Hinze-Selch D.; Haack M.; Zobel A.W.; Pollmacher T.

Weight gain during treatment with mirtazapine goes along with an increase in plasma levels of cytokines and leptin
pp. 272-273(2)
Authors: Kraus T.; Haack M.; Schuld A.; Pollmacher T.

Cognitive components of somatosensory evoked potentials in major depressive disorder
pp. 273-273(1)
Authors: Dietl T.; Dirlich G.; Vogl L.; Lechner C.; Nickel T.; Sonntag A.; Strian F.

The ''discontinuation syndrome'' in depressed patients successfully treated with sertraline
pp. 273-274(2)
Authors: Dan I.-A.; Simu M.

No evidence of lateralized effects on mood after slow repetitive transcranial magnetic stimulation (rTMS) in healthy volunteers
pp. 274-274(1)
Authors: Hermelink D.; Juckel G.; Zwanzger P.; Hampel H.; Moller H.-J.; Padberg F.

Suicidal behavior in patients with recurrent brief depression (RBD)
pp. 274-274(1)
Authors: Pezawas L.; Stamenkovic M.; Jagsch R.; Ackerl S.; Putz C.; Stelzer B.; Aschauer H.; Kasper S.

Auditory evoked potentials as indicator of serotonergic neuronal activity - An animal study using microinjection techniques into the dorsal raphe nucleus
pp. 275-275(1)
Authors: Juckel G.; Hegerl U.; Molnar M.; Csepe V.; Karmos G.

CRH, HPA system hyperactivity and depression
pp. 275-275(1)
Authors: Zobel A.W.; Nickel T.; Kunzel H.; Ackl N.; Sonntag A.; Ising M.; Holsboer F.

Cortisol response to the Dex/CRH test predicts medium-term-outcome in patients with remitted depression
pp. 275-276(2)
Authors: Zobel A.W.; Frieboes R.M.; Ising M.; Holsboer F.

The selective noradrenalin reuptake inhibitor induces similar sleep EEG changes like SSRI's in patients with depression
pp. 276-276(1)
Authors: Kuenzel H.E.; Murck H.; Ziegenbein M.; Held K.; Steiger A.

Modulation of sleep EEG and nocturnal hormone secretion by neuropeptide Y in patients with depression and normal controls
pp. 276-277(2)
Authors: Steiger A.; Held K.; Strohbusch S.; Antonijevic I.A.; Murck H.; Frieboes R.M.

Sleep-endocrine alterations in women with depression are markedly enhanced after menopause
pp. 277-277(1)
Authors: Antonijevic I.A.; Murck H.; Frieboes R.-M.; Steiger A.

Fast adaptive changes of the sleep regulatory system after the putative antidepressant EMD 68 843
pp. 277-278(2)
Authors: Murck H.; Frieboes R.M.; Antonijevic I.A.; Steiger A.

Onset of response to fluoxetine treatment as assessed by the symptom questionnaire
pp. 278-278(1)
Authors: Sonawalla S.; Hutchins A.; Delgado M.; Johnson M.; Worthington J.; Alpert J.; Fava M.

Citalopram versus amitriptyline in elderly patients with or without dementia. A Danish multicentre trial in general practice
pp. 278-278(1)
Authors: Rosenberg C.; Hopfner Petersen H.E.

Differential effect of chronic antidepressant treatments on lipopolysaccharide-induced depressive-like behavioural symptoms and the pro-/anti-inflammatory cytokine balance
pp. 278-279(2)
Authors: Kelly J.P.; Connor T.J.; Nolan Y.; Shen Y.; Leonard B.E.

Effects of reboxetine and sertraline treatments alone and in combination on the binding properties of cortical NMDA and ₁-adrenergic receptors in an animal model of depression
pp. 279-279(1)
Authors: Kelly J.P.; Harkin A.; Nally R.; Leonard B.E.

MRI signal hyperintensities and chronicity of depression
pp. 279-280(2)
Authors: Heiden A.; Kettenbach K.; Fischer P.; Schein B.; BaSsalamah A.; Frey R.; Gulesserian T.; Itzlinger U.; Trattnig S.; Imhof H.; Kasper S.

¹H-MR-Spectroscopy of untreated depressive patients shows reduced N-acetyl aspartate, choline and myo-inositol levels in the frontal lobe
pp. 280-280(1)
Authors: Frey R.; Gruber S.; Ortwein-Swoboda G.; Heiden A.; Mlynarik V.; Moser E.; Kasper S.

Reboxetine plus citalopram in treatment resistant depression
pp. 280-280(1)
Authors: Devarajan S.; Dursun S.M.

Dose-dependent antidepressive effect of new analogues of excitatory amino acids in forced swimming test
pp. 280-281(2)
Authors: Parshev V.V.; Onishchenko N.V.; Sergeyev V.S.; Piotrovsky L.B.; Petrov V.I.

Use of risperidone in psychotic and non-psychotic patients with bipolar disorder
pp. 281-281(1)
Authors: Petty F.; Sachs G.; Bowden C.

The effect of clonidine in the treatment of acute mania
pp. 281-281(1)
Author: Tudorache B.

Subjective evaluation of psychopharmacology and its outcome in schizophrenia
pp. 281-282(2)
Authors: Jarema M.; Murawiec S.; Szafranski T.; Koniczynska Z.; Szaniawska A.

A naturalistic study of changing attitudes of antipsychotic prescribing patterns in an inpatient service from Turkey
pp. 282-282(1)
Authors: Soykan A.; Ozsan H.; Celik S.

Low levels of antibodies to cardiolipin in first episode and chronic schizophrenia
pp. 282-283(2)
Authors: Sirota P.; Bodanov I.; Katzav A.; Hershko R.; Chapman J.

An open study of buspirone augmentation of neuroleptics in schizophrenic patients
pp. 283-283(1)
Authors: Sirota P.; Epstein B.; Benatov R.; Sousnostzky M.; Kindler S.

Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients
pp. 283-283(1)
Authors: Gonul A.S.; Basturk M.; Sofuoglu S.; Kula M.; Esel E.; Turan T.; Yabanoglu I.

Marked improvement in tardive dyskinesia with olanzapine treatment: a case report
pp. 283-284(2)
Authors: Esel E.; Sofuoglu S.; Turan M.T.; Gonul A.S.

A more favorable clinical outcome with sulpiride augmentation in a patient with chronic schizophrenia partially responsive to Olanzapine
pp. 284-284(1)
Authors: Witz S.; Kosov I.; Assael-Amini M.; Abramovich Y.

Risperidone is effective in patients with treatment-resistant schizophrenia
pp. 284-285(2)
Authors: Kocmur M.; Tavcar R.; Dernovsek M.Z.

Clozapine treatment of different psychoses
pp. 285-285(1)
Author: Gaszner P.

Contrasting effects of typical and atypical antipsychotics on neuronal viability and functioning of the anterior cingulate region in chronic schizophrenia: A MRSI study
pp. 285-286(2)
Authors: Braus D.F.; Ende G.; Weber-Fahr W.; Henn F.A.

Perception of chimeric faces and the brain's pattern of asymmetry in schizophrenia
pp. 286-286(1)
Authors: Kucharska-Pietura K.; Loza B.; Klimkowski M.

Perception of emotional prosody among schizophrenic patients
pp. 286-286(1)
Authors: Kucharska-Pietura K.; Loza B.

Behavioural asymmetry as a predictor of acute treatment efficacy in paranoid schizophrenia
pp. 286-287(2)
Authors: Loza B.; Kucharska-Pietura K.

Age-related factor structure of schizophrenic symptomatology
pp. 287-287(1)
Authors: Loza B.; Kucharska-Pietura K.

Implications of dichotic listening effects for dimensional structure of paranoid schizophrenia
pp. 287-288(2)
Authors: Loza B.; Kucharska-Pietura K.

Ziprasidone's effect on anxiety in a group of outpatients with stable schizophrenia
pp. 288-288(1)
Authors: Schooler N.R.; Siu C.

Improvement in cognition following a switch to open-label ziprasidone from olanzapine, risperidone and conventional antipsychotics
pp. 288-288(1)
Authors: Harvey P.D.; Meltzer H.Y.; Romano S.

Improvement in indices of health status following a switch to ziprasidone from conventional and novel antipsychotics
pp. 288-289(2)
Authors: Daniel D.G.; Weiden P.J.; O'Sullivan R.L.

Benefits of ziprasidone in stable outpatient schizophrenics switched from conventional antipsychotics, olanzapine, or risperidone
pp. 289-289(1)
Authors: Simpson G.M.; Potkin S.G.; Weiden P.J.; O'Sullivan R.L.

An overview of the efficacy and safety of rapid-acting intramuscular ziprasidone
pp. 289-289(1)
Authors: Daniel D.G.; Brook S.; Reeves K.R.

Pharmacokinetics of ziprasidone in children and adolescents with Tourette's syndrome
pp. 289-289(1)
Authors: Sallee F.R.; Miceli J.J.; Wilner K.D.; Robarge L.

Obesity as a risk factor for antipsychotic noncompliance
pp. 289-290(2)
Authors: Weiden P.J.; Mackell J.; McDonnell D.D.

Healthcare resource use and body mass index among individuals with schizophrenia
pp. 290-290(1)
Authors: Allison D.B.; Mackell J.

M100907 in schizophrenic and schizoaffective patients
pp. 290-290(1)
Authors: Kablinger A.S.; Freeman A.M.

The effect of risperidone on psychotic symptom and information processing in first episode schizophrenia
pp. 290-291(2)
Authors: Hyun S.B.; Kim J.G.; Hong K.S.; Kim E.

Brain activation in schizophrenic patients and healthy controls during working memory and mental arithmetic. a functional magnetic resonance imaging (fMRI) study
pp. 291-291(1)
Authors: Lund A.; Thomssen T.; Stordal K.; Kroken R.; Smievoll A.I.; Barndon R.; Ersland L.; Lundervold A.; Mjellem N.; Egeland J.; Rund B.; Hugdahl K.

Effects of new antipsychotics on serum prolactin and testosterone in schizophrenic patients
pp. 291-291(1)
Authors: Han D.H.; Park D.B.; Na C.

Longer-term effects of switching from typical to atypical antipsychotics in patients with stable schizophrenia
pp. 291-292(2)
Authors: Robinson G.; Wheeler A.; Byrd J.; Visser S.

Risperidone effect on positive and negative symptoms of schizophrenia: A nine-month follow-up study of 375 patients
pp. 292-292(1)
Authors: Cervera-Enguix S.; Giner J.; Ortuno F.; Pla J.; Soutullo C.; Fernandez A.

A comparison of the effects on cognitive function of E-5842 administered as a single or multiple dose
pp. 292-292(1)
Authors: Taubel J.; Arezina R.; Ward T.; Wesnes K.A.

Comparison of the costs and effects of treatment with risperidone versus olanzapine in daily practice
pp. 292-293(2)
Authors: Loos J.C.M.; Van Zonneveld T.H.; Loone A.J.M.

Comparison of indications and treatment outcomes of risperidone in elderly and younger patients
pp. 293-293(1)
Authors: Van Zonneveld T.H.; Loos J.C.M.; Loonen A.J.M.

DU 127090: a highly potent, atypical dopamine receptor ligand - a putative potent full spectrum antipsychotic with low EPS potential
pp. 293-293(1)
Authors: Van Vliet B.J.; Mos J.; Van der Heijden J.A.M.; Feenstra R.; Kruse C.G.; Long S.K.

DU 127090: a highly potent, atypical dopamine receptor ligand - high potency but low efficacy at dopamine D₂ receptors in vitro
pp. 294-294(1)
Authors: Van Vliet B.J.; Ronken E.; Tulp M.; Feenstra R.; Kruse C.G.; Long S.K.

DU 127090: a highly potent, atypical dopamine receptor ligand - pilot study of dopamine D₂ receptor occupancy after multiple oral administration of DU 127090 to healthy male volunteers, using ¹¹C-raclopride by means of positron emission tomography
pp. 294-294(1)
Authors: De Vries M.H.; Udo de Haes J.; Long S.K.; Grahnen A.; Nyman L.; Bergstrom M.; Wall A.; Langstrom B.

DU 127090: a highly potent, atypical dopamine receptor ligand - partial agonist character in neurochemistry assays in vivo
pp. 295-295(1)
Authors: Long S.K.; Feenstra R.; Kruse C.G.; Van Vliet B.J.

Impact of early intervention with intramuscular antipsychotic medication in an acute care setting
pp. 295-295(1)
Authors: Martinez J.M.; Russell J.M.; Salinas H.; Mackell J.A.

Relationship between inadequate physical healthcare and poor mental health among individuals with schizophrenia
pp. 295-296(2)
Authors: Russell J.M.; Mackell J.A.

Risperidone oral solution versus intramuscular haloperidol for control of psychotic agitation
pp. 296-296(1)
Authors: Currier G.W.; Simpson G.A.

Risperidone olanzapine drug outcomes study in schizophrenia (RODOS) pooled results from German centers
pp. 296-296(1)
Author: Albus M.

Cognitive symptoms in schizophrenic patients treated with risperidone compared to other neuroleptics
pp. 296-297(2)
Authors: Klauder A.; Rettig K.

An international survey on information needs of patients with schizophrenia and their carers and management issues most frequently encountered by professional care team members
pp. 297-297(1)
Authors: Waerner T.; Bassi M.; Dubuis J.; Fleischhacker W.W.; Kissling W.; Linszen D.; Remington G.; Turner T.; Wallace M.

A 3-week, double-blind, randomized trial of ziprasidone in the acute treatment of mania
pp. 297-297(1)
Authors: Keck P.E.; Ice K.; The Ziprasidone Mania Study Group

Reduced central muscarinic acetylcholine receptor availability in vivo in schizophrenic patients
pp. 298-298(1)
Authors: Raedler T.J.; Knable M.B.; Jones D.W.; Urbina R.A.; Gorey J.G.; Lee K.S.; Egan M.; Weinberger D.R.

Incomplete forms of the neuroleptic malignant syndrome: A continuation of a case series
pp. 298-298(1)
Authors: Zicanovic O.; Borisev L.; Borisev V.

Drug attitude inventory, spanish-adapted version
pp. 298-299(2)
Authors: Garcia Cabeza I.; Hormaechea Beldarrain J.A.; Sanz Amador M.; Arango Lopez C.; Gonzalez de Chavez M.

Compliance with neuroleptics in schizophrenic patients prior to inpatient treatment
pp. 299-299(1)
Authors: Rittmannsberger H.; Pachinger T.; Keppelmuller P.

Drug daily dosage in schizophrenia inpatients receiving conventional versus atypical neuroleptic agents
pp. 299-300(2)
Authors: Ritsner M.; Ponizovsky A.; Nechamkin Y.; Dahan M.; Caspi N.; Birman E.; Modai I.

Retrospective 1-year review of the outcomes of atypical antipsychotic use at Central Texas Veterans Health Care System
pp. 300-300(1)
Authors: Clark W.; Defilippi J.

Clinical predictors of acute response with quetiapine in psychotic mood disorders
pp. 300-300(1)
Authors: Zarate C.A.; Rothschild A.; Fletcher K.E.; Madrid A.; Zapatel J.

The effect of quetiapine in improving cognitive impairment in schizophrenia
pp. 300-301(2)
Author: Hellewell J.S.E.

Tolerability and patient satisfaction as determinants of treatment choice in schizophrenia: a multinational survey of the attitudes and perceptions of psychiatrists towards novel and conventional antipsychotics
pp. 301-301(1)
Authors: Hellewell J.S.E.; Gorman A.P.

Use of the number needed to treat to evaluate clinical trials of quetiapine and other atypical antipsychotics
pp. 301-302(2)
Author: Donoghue J.

Treatment of dementia patients with psychotic and behavioural symptoms with quetiapine and donepezil
pp. 302-302(1)
Authors: Parsa M.A.; Poggi E.; Barte L.

Efficacy of quetiapine compared with haloperidol and placebo in the short-term treatment of acute schizophrenia
pp. 302-303(2)
Author: Schulz S.C.

Safety during long-term exposure to quetiapine
pp. 303-303(1)
Authors: Gorman A.P.; Westhead E.K.

Global index of safety (GIS): a new instrument to assess drug safety: application to a prospective pharmacoepidemiological study (EFESO)
pp. 303-303(1)
Authors: Sacristan J.A.; Gomez J.C.; Badia X.; Kind P.; Gavart S.; The EFESO Study Group

New findings suggest weak anticholinergic profile of olanzapine
pp. 303-304(2)
Authors: Tran P.; Bymaster F.; Kennedy J.; Basson B.; Czekalla J.; Street J.; Clark S.

A double-blind study of intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients
pp. 304-304(1)
Authors: Wright P.; Birkett M.; Ferchland I.; David S.; Alaka K.; Pullen P.; Brook S.; Reinstein M.; Breier A.

Relapse prevention with olanzapine
pp. 304-304(1)
Authors: Beasley C.; Hamilton S.; Dossenbach M.

Effect of long-term olanzapine treatment on weight change in schizophrenia
pp. 305-305(1)
Authors: Gilmore J.; Kinon B.J.; Basson B.R.; Tollefson G.D.

Predictive value of early antianxiety effect on the acute-antipsychotic outcome: a comparison of fluphenazine and olanzapine
pp. 305-305(1)
Authors: Martenyi F.; Dossenbach M.; Jakovljevic M.; Metcalfe S.

Effective resolution of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia with olanzapine
pp. 305-306(2)
Authors: Kinon B.J.; Basson B.; Hill A.L.; Berg P.H.

Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone
pp. 306-306(1)
Authors: Kinon B.J.; Basson B.; Wang J.; Malcolm S.K.; Stauffer V.L.

Effects of risperidone and typical antipsychotics on basal ganglia volumes in patients with schizophrenia
pp. 306-306(1)
Authors: Honer W.G.; Lang D.J.; Vandorpe R.A.; Rui Q.; Smith G.N.; Milliken H.M.; Goghari V.M.; Kopala L.C.

Pharmacokinetics, tolerability, and safety of aripiprazole following single and multiple oral dose administration
pp. 306-307(2)
Authors: Mallikaarjun S.; Salazar D.E.; Bramer S.L.

Tolerability, efficacy and cognitive effects of quetiapine in patients with Parkinson's disease treated for psychotic symptoms
pp. 307-307(1)
Authors: Juncos J.L.; Evatt M.L.; Jewart R.D.; Roberts V.J.; Wood C.D.; Potter L.S.; Jou H.-C.; Yeung P.P.

Clozapine plasma levels and time to clinical response in a standardized trial
pp. 307-308(2)
Authors: La Pia S.; Fabrazzo M.; Bencivenga R.; Esposito G.; Pinto A.; Sannino A.; Maj M.

Atypical antipsychotics and dopamine D₁ receptor agonism: an in vivo experimental study using core temperature measurements in the rat
pp. 308-308(1)
Authors: Ahlenius S.; Oerther S.

Switch to risperidone and olanzapine in the cohort of young schizophrenic patients
pp. 308-309(2)
Authors: Chojnacka J.; Taflinski T.

The effect of atypical vs typical antipsychotic drugs on the results of neurocognitive tests in schizophrenic patients
pp. 309-309(1)
Authors: Rybakowski J.K.; Borkowska A.

Obsessive-compulsive symptoms in schizophrenic patients treated with clozapine
pp. 309-309(1)
Author: Taflinski T.

Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo
pp. 309-310(2)
Authors: Carson W.H.; Kane J.M.; Ali M.; Dunbar G.C.; Ingenito G.

Deficit/nondeficit schizophrenia: psychopathological evaluations and treatment
pp. 310-310(1)
Authors: Leuci E.; Marotta M.T.; Garlini S.; Uslenghi S.; Pelizza L.; Maggini C.

Risperidone Olanzapine Drug Outcomes Study (RODOS): the first English results
pp. 310-311(2)
Authors: Martin S.; Wright T.

Optimal risperidone dosage in drug-naive first-episode schizophrenic patients
pp. 311-311(1)
Authors: Kontaxakis V.P.; Havaki-Kontaxaki B.J.; Stamouli S.S.; Christodoulou G.N.

QTc prolongation associated with sulpiride and haloperidol use: A pilot crossover-design study
pp. 311-312(2)
Authors: Su K.P.; Chen K.P.; Shen W.W.; Tsai S.Y.

Neuroleptic malignant syndrome induced by risperidone and clozapine combination
pp. 312-312(1)
Authors: Kontaxakis V.P.; Havaki-Kontaxaki B.J.; Stamouli S.S.; Christodoulou G.N.

Olanzapine-induced neuroleptic malignant syndrome
pp. 312-313(2)
Authors: Kontaxakis V.P.; Havaki-Kontaxaki B.J.; Christodoulou N.G.; Paplos K.G.; Christodoulou G.N.

Olanzapine-associated neuroleptic malignant syndrome: Is there any overlap with the serotonin syndrome?
pp. 313-313(1)
Authors: Kontaxakis V.P.; Havaki-Kontaxaki B.J.; Christodoulou N.G.; Paplos K.G.; Christodoulou G.N.

Depression measures and motor side-effects among schizophrenic inpatients
pp. 313-313(1)
Authors: Kontaxakis V.P.; Havaki-Kontaxaki B.J.; Stamouli S.; Margariti M.; Kollias C.; Christodoulou G.N.

The use of atypical antipsychotics in the university psychiatric hospital in Athens
pp. 313-314(2)
Authors: Kontaxakis V.P.; Havaki-Kontaxaki B.J.; Kollias C.; Stamouli S.; Margariti M.; Christodoulou G.N.

Antipsychotic-induced parkinsonism in newly treated outpatients
pp. 314-314(1)
Authors: Schillevoort I.; Herings R.M.C.; Roos R.A.C.; Jansen P.A.F.; Leufkens H.G.M.

Neurological signs in schizophrenia patients: The influence of atypical versus classical antipsychotic drugs
pp. 314-315(2)
Authors: Boks M.P.M.; Russo S.; Knegtering R.; Den Boer J.A.; Van den Bosch R.J.

Dimensions of psychopathology in schizophrenia: a factor analysis of the amisulpride database
pp. 315-315(1)
Author: Rein W.

Low-dose amisulpride: some evidence for alertness-increasing properties in EEG studies
pp. 315-315(1)
Authors: Legangneux E.; Rosenzweig P.; Saletu B.; Allain H.

A one year cost-effectiveness model for the treatment of chronic schizophrenia in Belgium
pp. 316-316(1)
Authors: De Hert M.; Van Dijk M.; Lecomte P.; Nuyts G.

Inpatient treatment of schizophrenia: a real-life study of two leading atypical antipsychotics
pp. 316-317(2)
Authors: Kasper S.; Duchesne I.

A meta-analysis of efficacy and safety of risperidone and olanzapine
pp. 317-317(1)
Authors: Peuskens J.; De Hert M.; Jones M.

Long-term treatment with clozapine: a study with plasma levels
pp. 317-318(2)
Authors: Mauri M.C.; Laini V.; Scalvini M.; Cerveri G.; Ferrari V.; Volonteri L.S.; Giuliani E.; Papa P.

PPI deficits in antipsychotic-treated, chronic schizophrenic patients
pp. 318-318(1)
Authors: Ludewig K.; Leumann L.R.; Etzensberger M.; Vollenweider F.X.

A genetic polymorphism coding for 129Val in the prion protein is associated with decreased cortical gray matter volume in schizophrenic patients but not in controls
pp. 318-319(2)
Authors: Rujescu D.; Kirner A.; Giegling I.; Leinsinger G.; Hegerl U.; Moller H.J.; Meisenzahl E.M.

Resolution of rapid weight gain on olanzapine after substitution with quetiapine
pp. 319-319(1)
Author: Nasr S.J.

Successful use of high dose quetiapine in a patient with a psychiatric disorder resistant to olanzapine
pp. 319-320(2)
Authors: Robertson J.B.; Treosti L.; Walker K.D.

Quetiapine is effective in a high-risk patient without precipitating the akathisia seen with olanzapine and risperidone
pp. 320-320(1)
Author: Purdon S.

Modulation of D₂R-mediated mitogenic signalling by APDs
pp. 320-321(2)
Authors: Rogue P.; Gensburger C.; Freyermuth S.; Malviya A.

Clozapine is efficient in long-term treatment of negative syndrome, but no cognitive functioning, in schizophrenia? A three-year follow-up study
pp. 321-321(1)
Authors: Marinkovic D.; Totic S.; Jasovic-Gasic M.; Maric N.; Paunovic V.R.

Olanzapine vs haloperidol: plasma levels and clinical efficacy on cognitive function in 37 schizophrenic patient (22 olz, 15 hal.)
pp. 321-321(1)
Authors: De Vanna M.; Anzallo C.; Onor M.L.; Aguglia E.

Differential actions of the new antipsychotic agents
pp. 321-322(2)
Authors: Moore N.A.; Bymaster F.P.; Tran P.; Breier A.; Tollefson G.D.

Dopamine and serotonin plasma blood level in adolescents with schizophrenia during perphenazine therapy
pp. 322-322(1)
Authors: Rajewski A.; Adamczewska-Goncarzewicz Z.; Dorszewska J.; Rajewska J.

The use of quantitative magnetic resonance imaging and auditory evoked potentials in schizophrenic patients
pp. 322-322(1)
Authors: Meisenzahl E.M.; Muller D.; Frodl T.; Marcuse A.; Leinsinger G.; Juckel G.; Heiss D.; Unger J.; Moller H.-J.; Hegerl U.

Evaluation of working memory in functional MR imaging with different memory tasks
pp. 323-323(1)
Authors: Meisenzahl E.M.; Kathmann N.; Heiss D.T.; Zetzsche T.; Hahn K.; Leinsinger G.L.; Moller H.-J.

Cortical surface and regional variability in patients with schizophrenia and healthy controls
pp. 323-323(1)
Authors: Meisenzahl E.M.; Holder J.J.; Marcuse A.; Preuss U.; Leinsinger G.; Zilles K.; Moller H.J.; Schormann T.

Quantitative magnetic resonance imaging of the corpus callosum in schizophrenia
pp. 324-324(1)
Authors: Frodl T.; Holder J.; Greiner J.; Marcuse A.; Leinsinger G.; Heiss D.; Hegerl U.; Moller H.-J.; Meisenzahl E.M.

In vivo striatal dopamine D₂ receptor binding in drug-naive patients with schizophrenia compared to healthy controls: an ¹²³I-IBZM-SPECT study
pp. 324-324(1)
Authors: Frodl T.; Schmitt G.J.E.; Dresel S.; Tatsch K.; Moller H.-J.; Meisenzahl E.M.

Striatal dopamin transporter in drug-naive schizophrenic patients: a ^99mTc-TRODAT-1-SPECT study
pp. 324-324(1)
Authors: Schmitt G.J.E.; Frodl T.; Tatsch K.; Dresel S.; Moller H.-J.; Meisenzahl E.M.

Combined striatal dopamin transporter and dopamin D2-receptor-SPECT in drug-naiv schizophrenic patients: a ^99mTc-TRODAT-1-¹²³I-IBZM-SPECT study
pp. 324-325(2)
Authors: Meisenzahl E.M.; Schmitt G.J.E.; Frodl T.; Tatsch K.; Moller H.-J.; Dresel S.

In vivo effects of olanzapine and risperidone on striatal dopamine D₂ receptor binding in schizophrenic patients: an ¹²³I-IBZM SPECT study
pp. 325-325(1)
Authors: Meisenzahl E.M.; Frodl T.; Schmitt G.J.E.; Dresel S.; Tatsch K.; Mager T.; Moller H.-J.

Amygdala or ventral hippocampal lesions at two early stages of life differentially affect prepulse inhibition of the acoustic startle response; an animal model of a neurodevelopmental disorder like schizophrenia
pp. 325-325(1)
Authors: Daenen E.W.P.M.; Wolterink G.; Van Der Heyden J.A.; Kruse C.G.; Van Ree J.M.

Risperidone versus pimozide for the treatment of monosymptomatic hypochondriacal psychosis
pp. 325-326(2)
Authors: Cetin M.; Ebrinc S.

Meta-analysis of amisulpride - A selective dopamine receptor antagonist with an ''atypical'' profile
pp. 326-326(1)
Authors: Leucht S.; Pitschel-Walz G.; Kissling W.

Neuropsychological deficits and negative symptoms in patients with first-episode schizophrenia
pp. 326-327(2)
Authors: Schaub A.; Wolf B.; Charypar M.; Moller H.-J.

Coping-orientated treatment and atypical neuroleptics in an integrated treatment approach for patients with schizophrenia
pp. 327-327(1)
Authors: Schaub A.; Wolf B.; Gartenmaier A.; Kaiser A.; Muller N.; Moller H.-J.

Drug combination treatment in acute and subacute states of schizophrenia and schizoaffective disorder
pp. 327-328(2)
Authors: Muller M.J.; Benkert O.

Costs-benefits of resource utilization in the Quebec welfare recipients population using two atypical drug products
pp. 328-328(1)
Authors: Castilloux A.-M.; Savoie M.; LeLorier J.

Sleep quality and early morning wakefulness of schizophrenic patients treated with olanzapine compared to chlorpromazine
pp. 328-329(2)
Author: Dossenbach M.

Olanzapine vs. chlorpromazine - 6 weeks treatment of acute schizophrenia
pp. 329-329(1)
Author: Dossenbach M.

Effects of an atypical neuroleptic EMD 128 130 on sleep EEG and nocturnal hormone secretion in young normal controls
pp. 329-330(2)
Authors: Held K.; Frieboes R.M.; Murck H.; Kunzel H.; Ziegenbein M.; Steiger A.

Amisulpride: kinetics in patients with renal failure
pp. 330-330(1)
Authors: Canal M.; MacMahon M.; Kwan J.; Dubruc C.

No effect of amisulpride on lithium pharmacokinetics
pp. 330-331(2)
Authors: Canal M.; Chaufour S.; Zieleniuk I.; Borgstein N.G.; Pinquier J.L.

Amisulpride pharmacokinetics: No difference between young and elderly subjects
pp. 331-331(1)
Authors: Canal M.; Chaufour S.; Lavanant C.; Zieleniuk I.; Piette J.F.; Deschamps C.

Amisulpride does not inhibit cytochrome P450 isozymes
pp. 331-332(2)
Authors: Gillet G.; Dormerque L.; Canal M.; Thenot J.P.

Risperidone is more useful than bromperidol in the treatment of first-episode schizophrenic patients
pp. 332-332(1)
Author: Suhiyoshi A.

Can quality management improve the treatment of schizophrenic outpatients?
pp. 332-333(2)
Authors: Seemann U.; Kissling W.; Zacher A.

Decreased GSK-3b immunoreactivity in postmortem frotal cortex of schizophrenic patients
pp. 333-333(1)
Authors: Kozlovsky N.; Belmaker R.H.; Agam G.

Haptoglobin phenotypes and genotypes in schizophrenia
pp. 333-333(1)
Authors: Maes M.; Bocchio L.; Zanardini R.; Bignotti S.; Tura G.B.; Pioli R.; Delanghe J.; Altamura C.A.

DU 127090: A highly potent, atypical dopamine receptor ligand - Behavioral effects of DU 127090 in Cebus non-human primates
pp. 333-333(1)
Authors: Casey D.E.; Van Vliet B.J.; Feenstra R.; Kruse C.G.; Long S.K.

Fatal neuroleptic intoxications identified at autopsy in Vienna from 1991 to 1997
pp. 333-334(2)
Authors: Schreinzer D.; Frey R.; Stimpfl T.; Vycudilik W.; Berzlanovich A.; Kasper S.

Mezapam reduces basophil releasability in non-atopic allergic skin diseases
pp. 334-334(1)
Authors: Strakhova M.; Cheburkin A.; Raba G.

Frontal and temporal enlargement of CSF spaces in agoraphobia: a morphometric CT-scan study
pp. 334-334(1)
Authors: Wurthmann C.; Gregor J.; Bogerts B.

Psychiatric disorders and comorbidity in high-dose and low-dose benzodiazepine users
pp. 334-335(2)
Authors: Lekka N.P.; Paschalis C.; Ellul J.; Beratis S.

Anxiolytic like activity of cyamemazine in mice models of anxiety
pp. 335-335(1)
Authors: Bourin M.; Hascoet M.; Colombel M.C.

A placebo-controlled study of sertraline in generalized social phobia
pp. 335-335(1)
Authors: Van Ameringen M.A.; Swinson R.; Walker J.R.; Lane R.M.

24-Week prevention of relapse of generalized social phobia study in responders to 20-weeks of sertraline treatment
pp. 336-336(1)
Authors: Van Ameringen M.A.; Walker J.R.; Swinson R.; Lane R.M.

Efficacy of venlafaxine ER in social adjustment in patients with generalized anxiety disorder
pp. 336-336(1)
Authors: Boyer P.; Mahe V.; Hackett D.; Haudiquet V.

Efficacy of short and long-term venlafaxine ER treatment on somatic and psychic symptoms of GAD
pp. 337-337(1)
Authors: Hackett D.; Meoni P.; White C.; Rasmussen J.

Cholecystokinin-antisense oligodeoxynucleotides: a new strategy in the approach to anxiety?
pp. 337-337(1)
Authors: Cohen H.; Kotler M.

Venlafaxine ER treatment of GAD: specific benefit of long-term treatment
pp. 337-338(2)
Authors: Meoni P.; Hackett D.; Montgomery S.A.

Survival analyses of discontinuations as evidence of long-term effectiveness of venlafaxine ER in GAD: comparison of venlafaxine ER with placebo
pp. 338-339(2)
Authors: Montgomery S.A.; Mahe V.; Haudiquet V.; Hackett D.

Improvement of CCK-4 induced panic by selective GABA-transaminase-inhibition with vigabatrin
pp. 339-339(1)
Authors: Zwanzger P.; Baghai T.; Schule C.; Minov C.; Padberg F.; Schwarz M.; Moller H.-J.; Rupprecht R.

Neuroendocrinological, biochemical and psychophysiological characteristics of chronic posttraumatic stress disorder
pp. 339-339(1)
Authors: Klumpers U.M.H.; Tulen J.H.M.; Timmerman L.; Fekkes D.; Boomsma F.; Pepplinkhuizen L.; Loonen A.J.M.

Thalamic blood flow is reduced in OCD responders to fluvoxamine
pp. 339-339(1)
Authors: Ho Pian K.L.; Westenberg H.G.M.; Van Megen H.G.M.; Ramsey N.; Van Rijk P.P.

Orphanin FQ, an endogenous modulator of stress-induced anxiety states in animals
pp. 339-340(2)
Authors: Moreau J.-L.; Ouagazzal A.M.; Jenck F.

Gammahydroxybutyrate (GHB) exhibits anxiogenic-like effects in the ''elevated plus maze test'' in male mice
pp. 340-340(1)
Authors: Navarro J.F.; Maldonado E.; Pedraza C.; Garcia F.; Luna G.

Effects of tiapride on anxiety tested in the light-dark box in male mice
pp. 340-341(2)
Authors: Cardenas J.; Navarro J.F.; Maldonado E.; Beltran D.

Effects of 3,4-methylenedioxymethamphetamine (''ecstasy'') on anxiety in the ''social interaction test'' in male mice
pp. 341-341(1)
Authors: Maldonado E.; Navarro J.F.; Cardenas J.; Davila G.; Cavas M.

Acute and subchronic effects of MDMA (''ecstasy'') on anxiety in the ''elevated plus maze test'' in male mice
pp. 341-342(2)
Authors: Maldonado E.; Navarro J.F.; Romero C.; Martin M.; Beltran D.

Risperidone vs. olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder: Safety comparisons
pp. 342-342(1)
Authors: Conley R.R.; Mahmoud R.; The Risperidone Study Group

Efficacy of risperidone vs. olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder
pp. 342-343(2)
Authors: Conley R.R.; Mahmoud R.

Autonomic neurocardiac effects of benzodiazepines: A comparison between midazolam, diazepam and lorazepam
pp. 343-343(1)
Authors: Agelink M.W.; Lemmer W.; Majewski T.; Klieser E.

Effects of selective 5-HT_2C receptor antagonist, SB 242084, on anxiety and depressive-like behaviour in mice
pp. 344-344(1)
Authors: Sukhotina I.A.; Zvartau E.E.

Exploratory pilot study with olanzapine in generalized anxiety disorder (GAD) showed anxiolytic treatment with low-dosages of the atypical antipsychotic
pp. 344-344(1)
Authors: Klieser E.; Wurthmann C.; Czekalla J.; Landefeld H.; Lemmer W.; Schulte T.

Three randomised, placebo-controlled, double-blind trials of pregabalin treatment of Generalized Anxiety Disorder (GAD)
pp. 344-344(1)
Authors: Pande A.C.; Crockatt J.G.; Feltner D.E.; Liu-Dumaw M.; Werth J.L.; Pregabalin GAD Study Group

A placebo-controlled, double-blind study of pregabalin treatment of social phobia: Outcome and predictors of response
pp. 344-345(2)
Authors: Feltner D.E.; Pollack M.H.; Davidson J.R.T.; Stein M.B.; Futterer R.; Jefferson J.W.; Lydiard R.B.; DuBoff E.; Robinson P.; Phelps M.; Slomkowski M.; Werth J.L.; Pande A.C.

Frontal lobe dysfunction and prediction to treatment outcome in obsessive-compulsive disorder
pp. 345-345(1)
Authors: Cavedini P.; Riboldi G.; D'Annucci A.; Cisima M.; Bellodi L.

Modulation of the serotonergic system and anxiety sensitivity
pp. 345-345(1)
Authors: Romano P.; Ieva A.; Piccinini G.; Rolla A.S.; Bellodi L.; Perna G.

The role of the balance system in panic disorder
pp. 346-346(1)
Authors: Perna G.; Caldirola D.; Bussi R.; Rolla A.S.; Alpini D.; Cesarani A.; Bellodi L.

Improved avoidance learning by oxytocin administration in a high-emotional strain of Sprague-Dawley rats
pp. 346-346(1)
Authors: Hillegaart V.; Uvnas-Moberg K.; Eklund M.; Ahlenius S.

Diurnal variation of cortisol in panic disorder
pp. 346-347(2)
Authors: Bandelow B.; Wedekind D.; Sandvoss V.; Broocks A.; Hajak G.; Pauls J.; Peter H.; Ruther E.

Predictors of treatment response in Panic disorder
pp. 347-347(1)
Authors: Menini M.; Paulillo G.; Gariboldi S.; Avanzini M.; Amore M.; Maggini C.

Paroxetine is effective in the treatment of generalized anxiety disorder: results from a randomized placebo-controlled flexible dose study
pp. 347-348(2)
Authors: McCafferty J.P.; Bellew K.; Zanelli R.; Iyengar M.; Hewett K.

Separation of systemic physiologic and specific cerebral drug effects in pharmacologic magnetic resonance imaging (phMRI)
pp. 348-348(1)
Authors: Kalisch R.; Elbel G.K.; Schieferstein O.; Czisch M.; Auer D.P.

Sertraline and posttraumatic stress disorder: Results of 24 weeks of open-label sertraline followed by a 28-week discontinuation study
pp. 348-349(2)
Authors: Davidson J.; Londborg P.; Pearlstein T.; Rothbaum B.; Brady K.; Farfel G.

The anxiolytic-like effect of nafadotride, a dopamine D₃ receptor antagonist, in rats
pp. 349-349(1)
Authors: Rogoz Z.; Klozinska A.; Maj J.

Risperidone augmentation in refractory obsessive compulsive disorder: An open-label study
pp. 349-350(2)
Authors: Pfanner C.; Marazziti D.; Dell'Osso L.; Presta S.; Gemignani A.; Milanfranchi A.; Cassano G.B.

Sleep EEG changes in OCD: A comparison with normal controls
pp. 350-350(1)
Authors: Matos-Pires A.; Cavaglia F.; Pires-Barreira D.; Lara E.; Atalaia A.; Arriaga F.

Generalised anxiety disorder: An insight into the burden on the individual and society
pp. 350-351(2)
Author: Wittchen H.-U.

Improving impairment and disability in anxiety disorders with paroxetine treatment
pp. 351-351(1)
Authors: Baldwin D.S.; Birtwistle J.

The burden of post-traumatic stress disorder
pp. 351-352(2)
Author: Nutt D.J.

Rehabilitation of refugees and forced migrants with social-stress disorders in Russia
pp. 352-352(1)
Authors: Prokudina E.N.; Prokudin V.N.; Muzychenko A.P.

The use of citalopram in resistant OCD
pp. 352-353(2)
Author: Marazziti D.

Treatment of somatophorm disorders in Russian' hospitals
pp. 353-353(1)
Authors: Prokudin V.N.; Muzychenko A.P.; Sharaev P.I.; Khoundanov L.L.

Double-blind trial of paroxetine for specific phobia
pp. 353-353(1)
Authors: Benjamin J.; Ben-Zion I.Z.; Dannon P.

Tolerance to the anxiogenic-like effect of mCPP in the rat elevated zero-maze test after subchronic administration
pp. 354-354(1)
Authors: Lightowler S.; Goetghebeur P.; Vickers S.P.; Bickerdike M.J.; Kennett G.A.

The model of timid-defensive behaviour in mice: Psychotropic effects of the different treatments
pp. 354-354(1)
Authors: Verbitskaya E.V.; Belozertseva I.V.; Sukhotina I.A.; Vekovischeva O.Y.

Benzodiazepines effects evaluation based on experimental pharmacogenetic data in humans
pp. 354-355(2)
Authors: Nadorov S.A.; Badyshtov B.A.; Kolotilinskaya N.V.

A randomized, double-blind, placebo-controlled trial with cerebrolysin in Alzheimer's disease
pp. 355-355(1)
Authors: Panisset M.; Gauthier S.; Moessler H.; Windisch M.

The MAD-B study - A randomized, double-blind, placebo-controlled trial with cerebrolysin in Alzeimer's disease
pp. 355-355(1)
Authors: Ruether E.; Moessler H.; Windisch M.

Cerebrolysin in the treatment of dementia: open-label study with a neurotrophic agent
pp. 355-356(2)
Authors: Rainer M.; Moessler H.

Co-occurrence of OCD and HD in a nuclear family
pp. 356-356(1)
Authors: De Marchi N.; Ariano M.G.; Ragone M.A.; Daniele F.; Dama A.

Bidirectional pharmacological treatment (selegiline and donepezil) in cognitive impairment of Alzheimer Disease - A possibility
pp. 356-357(2)
Authors: Gheorghe M.D.; Grigorescu G.

Neuroleptic malignant syndrome in an 72-year-old-man with Alzheimer's disease: a case report and review of the literature
pp. 357-357(1)
Authors: Gallarda T.; Olie J.-P.

Clinical characteristics in psychogeriatric patients with orthostatic hypotension and low blood pressure
pp. 357-357(1)
Authors: Zacharof A.K.; Zacharof H.

Follow-up investigation in patients with Alzheimer's disease 24 weeks after termination of cerebrolysin therapy
pp. 357-358(2)
Authors: Ruether E.; Gmeinbauer R.; Windisch M.

Perception of facial affect among unilateral brain-damaged patients
pp. 358-358(1)
Authors: Kucharska-Pietura K.; Loza B.; Klimkowski M.; Dropko P.

Intrahippocampal infusion of an equimolar dose of endogenous -, , - and ORL1-receptor agonists. Effects on spatial learning in the rat
pp. 358-358(1)
Authors: Sandin J.; Ogren S.O.; Terenius L.

Naftidrofuryl in the treatment of vascular dementia (NaVaDe study)
pp. 359-359(1)
Authors: Moller H.J.; Hartmann A.; Kessler C.; Brown T.; Gamand S.

Effects of donepezil on behaviour and other domains in moderate to severe Alzheimer's disease
pp. 359-360(2)
Authors: Gauthier S.; Feldman H.; Hecker J.; Vellas B.; Subbiah P.; Whalen E.

Neuro-radiological findings and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo-controlled clinical trials in vascular dementia
pp. 360-360(1)
Authors: Wilcock G.; Stoeffler A.; Sahin K.; Moebius H.J.

Donepezil for Alzheimer's Disease - The donald study - a multicenter 24 weeks clinical trial in Germany
pp. 360-361(2)
Authors: Froelich L.; Gertz H.-J.; Heun R.; Heuser I.; Jendroska K.; Kornhuber J.; Kurz A.; Mueller-Thomsen T.; Ries F.; Waechtler C.; Metz M.; Goebel C.

Processing deficits and overall cognitive impairment in Alzheimer Disease
pp. 361-361(1)
Authors: Politis A.; Maillis A.; Oulis P.; Christodoulou G.N.; Stefanis C.N.

Decreasing the risk of tardive dyskinesia
pp. 361-361(1)
Authors: Chirita R.; Chirita V.; Stefanescu C.

Alpha-2-macroglobulin polymorphism and Alzheimer's dementia
pp. 361-362(2)
Authors: Juhasz A.; Rimanoczy A.; Kalman J.; Janka Z.

Test-retest reliability and concurrent validity of the SADIMoD
pp. 362-362(1)
Authors: Loonen A.J.M.; Doorschot C.H.; Van Hemert D.A.; Oostelbos M.C.J.M.; Sijben A.E.S.

Interrater reliability and construct validity of the SADIMoD
pp. 362-363(2)
Authors: Loonen A.J.M.; Doorschot C.H.; Van Hemert D.A.; Oostelbos M.C.J.M.; Sijben A.E.S.; The MASEAS Team

A double-blind, randomized, placebo controlled study of the effects on wake EEG of 2 doses of naftidrofuryl using a cross-over design in elderly healthy male volunteers
pp. 363-363(1)
Authors: Boeijinga P.H.; Muzet M.; Gamand S.; d'Aniello F.; Parot P.; Luthringer R.; Macher J.-P.

Results of a placebo-controlled 6-month trial with memantine in moderate to severe Alzheimer's disease (AD)
pp. 363-364(2)
Authors: Reisberg B.; Ferris S.; Sahin K.; Windscheif U.; Mobius H.J.

Colostrinin - a polypeptide isolated from early milk, for treatment of Alzheimer's disease
pp. 364-364(1)
Authors: Leszek J.; Inglot A.D.; Janusz M.; Lisowski J.; Kiejna A.; Georgiades J.

The effect of various 1,2,3,4-tetrahydroisoquinoline derivatives on ³H-dopamine and ³H-serotonin uptake in rat brain structures - In vitro studies
pp. 364-364(1)
Authors: Michaluk J.; Mokrosz M.; Antkiewicz-Michaluk L.

Distinct differences in neurochemical effects produced by various 1,2,3,4-tetrahydroisoquinolines on dopaminergic structures of rat brain
pp. 365-365(1)
Authors: Antkiewicz-Michaluk L.; Mokrosz M.; Romanska I.; Vetulani J.

Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in patients with Alzheimer's dementia
pp. 365-366(2)
Authors: Street J.; Clark S.; Juliar B.; Feldman P.; Kadam D.; Breier A.

Microdialysis in parkinsonian patient basal ganglia: apomorphine effect without changes in the release of neuroactive amino acids
pp. 366-366(1)
Authors: Fedele E.; Stefani A.; Bassi A.; Ansaldo M.A.; Raiteri M.; Mazzone P.; Altibrandi M.G.; Stanzione P.

Behavioral and biochemical studies on the central effects of midazolam and allopregnanolone
pp. 366-366(1)
Authors: Czlonkowska A.; Siemiatkowski M.; Bidzinski A.; Plaznik A.

The targeted disruption of the adenosine A_2A receptor in mice reduces hypokinesia caused by haloperidol or reserpine and catalepsy induced by various drugs
pp. 366-367(2)
Authors: El Yacoubi M.; Ledent C.; Parmentier M.; Costentin J.; Vaugeois J.-M.

Efficacy and safety of donepezil in patients with Alzheimer's disease: preliminary findings from the Australian subset of a global clinical experience study
pp. 367-367(1)
Authors: Brodaty H.; Bahra R.; Zhang R.; O'Leary M.; Short K.; Barrington M.; The Australian Donepezil Study Group

A multiple-dose study of the pharmacokinetics of donepezil and sertraline in healthy volunteers
pp. 367-368(2)
Authors: Nagy C.F.; Latimer F.E.; Kumar D.; Perdomo C.A.; Wason S.; Cullen E.I.; Pratt R.D.

Donepezil improved or stabilized cognition over one year in patients with mild and moderate Alzheimer's disease
pp. 368-368(1)
Authors: Engedal K.; Soininen H.; Verhey F.; Waldemar G.; Winblad B.; Wimo A.; Wetterholm A.-L.; Zhang R.; Haglund A.; Subbiah P.; The Donepezil Nordic Study Group

Tolerability and safety of donepezil in the treatment of Alzheimer's disease: results from a Post Marketing Surveillance study
pp. 368-368(1)
Authors: Sramko C.A.; Berger F.; Calabrese P.; Frolich L.

Donepezil provides relevant therapeutic benefits in different domains to ''real world'' patients with Alzheimer's disease
pp. 369-369(1)
Authors: Berger F.; Sramko C.-A.; Frolich L.; Calabrese P.

Screening for cognitive impairment in dementia - the DemTect procedure
pp. 369-369(1)
Authors: Calabrese P.; Kessler J.

Steady-state pharmacokinetics of donepezil hydrochloride in subjects with hepatic disease
pp. 369-370(2)
Authors: Reyes J.F.; Vargas R.; Kumar D.; Perdomo C.A.; Cullen E.I.; Pratt R.D.

New approaches in the treatment of brain lesions
pp. 370-370(1)
Authors: Epifanova N.; Koukchina A.; Epifanov I.

Multiple Sclerosis (MS) resembling Landau Kleffner (LK) syndrome
pp. 370-371(2)
Author: Kountouris D.

Increased diagnostic accuracy in Alzheimer's disease by age-transformed hippocampal volumes
pp. 371-371(1)
Authors: Teipel S.J.; Bayer W.; Alexander G.E.; Schapiro M.B.; Moller H.-J.; Rapoport S.I.; Hampel H.

Cerebrospinal fluid tau phosphorylated at threonine 231 compared to total tau in Alzheimer's disease patients, controls, and subjects at risk
pp. 371-371(1)
Authors: Burger K.; Kohnken R.; Teipel S.J.; Shen J.; Zinkowski R.; Hofmann-Kiefer K.; Moller H.-J.; Rapoport S.I.; Hampel H.

Progression of corpus callosum and hippocampus atrophy as independent markers of structural disease progression in Alzheimer's disease
pp. 371-372(2)
Authors: Hampel H.; Teipel S.J.; Bayer W.; Alexander G.E.; Schapiro M.B.; Moller H.-J.; Rapoport S.I.

Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer's disease brain
pp. 372-373(2)
Authors: Hampel H.; Scheloske M.; Haslinger A.; Padberg F.; Fischer P.; Unger J.; Teipel S.J.; Rosenberg C.; Oshida R.; Hulette C.; Pongratz D.; Moller H.-J.

Oral Mg²⁺-supplementation reverses age related sleep-endocrine changes in humans
pp. 373-373(1)
Authors: Murck H.; Held K.; Antonijevic I.A.; Kunzel H.; Golly I.C.; Steiger A.

Repetitive transcranial magnetic stimulation: Evidence for neuroprotective effects
pp. 373-373(1)
Authors: Post A.; Muller M.B.; Engelmann M.; Keck M.E.

Efficacy of risperidone treatment for psychoses associated with paraphrenia, vasular, senile or Parkinson's dementia in 10 geriatric patients: A case series
pp. 373-374(2)
Authors: Krsteska R.; Velkov V.; Filovska V.

Psychological effects of MDMA (''Ecstasy'') after pretreatment with selective neuroreceptor ligands in healthy volunteers
pp. 374-374(1)
Authors: Liechti M.E.; Gamma A.; Hell D.; Vollenweider F.X.

The influence of the nitric oxide synthase inhibitor L-NAME on the effects of ethanol in rats after acute ethanol administration
pp. 374-375(2)
Authors: Pokk P.; Vassiljev V.; Vali M.

MAO-B activity in early and late alcohol withdrawal
pp. 375-375(1)
Authors: Basturk M.; Kose K.; Sofuoglu S.; Esel E.; Yabanoglu I.; Gonul A.S.; Yazici C.; Turan T.

Periodic postpartum separation from the litter alters stress-reactivity and sensitivity to morphine in Long-Evans dams
pp. 375-376(2)
Authors: Kalinichev M.; Easterling K.W.; Holtzman S.G.

Depression, smoking, and cortisol response to stress
pp. 376-376(1)
Authors: Netter P.; Jooss S.; Conrad N.; Rohrmann S.; Toll C.

Neuroendocrine effects of ethanol in sons of alcoholics
pp. 376-377(2)
Authors: Spring K.; Zimmermann U.; Lachner G.; Holsboer F.

Serotonin antibodies in treatment of experimental opiate addiction: Mechanisms of action
pp. 377-377(1)
Authors: Basharova L.; Vetrile L.; Trekova N.; Mikovskaya O.

Combination treatment for chronic hepatitis C with interferon-alpha and ribavirin in psychiatric patients and drug addicts compared to controls
pp. 377-378(2)
Authors: Schafer M.; Schmidt F.; Soyka M.; Moller H.-J.; Loeschke K.

Changes of ANP plasma concentrations in alcoholics during withdawal
pp. 378-378(1)
Authors: Kiefer F.; Jahn H.; Andersohn F.; Kellner M.; Naber D.; Wiedemann K.

5-HT_2B/2C but not 5-HT_2A receptor subtypes modulate the impulse flow dependent release of DA in the rat nucleus accumbens and striatum: Studies with morphine and amphetamine
pp. 378-378(1)
Authors: Porras G.; Lucas G.; Caccia S.; Spampinato U.

Role of corticosterone and its synthesis inhibition in the discriminative stimulus effects of cocaine in rats
pp. 378-379(2)
Authors: Przegalinski E.; Filip M.; Nowak E.; Siwanowicz J.

The role of the NMDA system in alcohol dependence - Dextromethorphan challenge in alcoholics and controls: Subjective response, neuroendocrinological findings, in vivo metabolic activation and clinical implications
pp. 379-379(1)
Authors: Schutz C.G.; Eisenburg B.; Ruther T.; Bondy B.; Soyka M.

Increased O-demethylation rate of dextromethorphan in alcohol dependent patients. A possible role of ethanol in changing cytochrome P450 2D6 activity
pp. 379-380(2)
Authors: Eisenburg B.; Schutz C.G.; Kuss J.P.; Heumuller M.; Soyka M.

Effects of long-term voluntary ethanol intake on the relative expression of NMDA receptor subunits and splice variants in the rat brain
pp. 380-380(1)
Authors: Rader H.; Holter S.M.; Rujescu D.

Flunitrazepam compared to Nitrazepam and placebo at alcoholics
pp. 380-381(2)
Authors: Lazarova V.; Jakovcevska-Kujundziska M.; Filovska V.; Vulovska M.

Use of Alprazolam in the treatment of apstinential syndrome with alcoholics
pp. 381-381(1)
Authors: Jakovcevska-Kujundziska M.; Lazarova V.; Filovska V.; Vulovska M.

Serotonin transporter gene regulatory region polymorphism (5-HTTLPR), [3H]-paroxetine binding in healthy controls and alcohol dependants and its relation to impulsivity
pp. 381-381(1)
Authors: Preuss U.W.; Soyka M.; Bahlmann M.; Wenzel K.; Behrens S.; De Jonge S.; Kruger M.; Bondy B.

No association between suicidal behaviour and 5-HT2A-T102C polymorphism in alcohol dependants
pp. 382-382(1)
Authors: Preuss U.W.; Koller G.; Bahlmann M.; Soyka M.; Bondy B.

Naltrexone in the treatment of craving in opiate addicts
pp. 382-382(1)
Authors: Ramah A.; Todorovic M.

Therapeutic efficiency coaxil at treatment of alcoholism
pp. 382-383(2)
Authors: Bokhan N.; Semke V.

The behavioral effects of L-tryptophan and p-chlorophenylalanine in rats with different levels of corticosteroids
pp. 383-383(1)
Authors: Fedotova J.O.; Sapronov N.S.

Ethimizol effect on the acoustical function by method audiometry (registration of acoustic evoked potentials)
pp. 383-384(2)
Author: Petrova N.N.

Humoral component of regeneration and learning is a subcase of neurosecretion
pp. 384-384(1)
Authors: Sapronov N.S.; Stepanov I.I.

The comparative analysis of NMDA blocking activity and safety of mono- and bis-cationic compounds in tests in animals
pp. 384-385(2)
Authors: Sapronov N.S.; Gmiro V.E.; Serdyuk S.E.

A reversible animal models of neuromotor diskinesias, proposed by intrastriatal multiple drugs microinjection
pp. 385-385(1)
Authors: Tkachenko B.I.; Yakimovski A.F.; Kuteeva E.B.

Asperger's disorder in the emergency psychiatric setting
pp. 385-386(2)
Authors: Raja M.; Azzoni A.

Role of serotonin and serotonin receptors in the apomorphine-induced aggressive behaviour of adult male Wistar rats
pp. 386-386(1)
Authors: Matto V.; Skrebuhhova-Malmros T.; Rudissaar R.; Pruus K.; Allikmets L.

Pharmacological control of aggressivity in mentally retarded adults
pp. 386-386(1)
Authors: Bertelli M.; Notarelli A.; La Malfa G.

Informative morphogenetic variants in bipolar affective disorder
pp. 386-387(2)
Authors: Tenyi T.; Csabi G.; Herold R.; Trixler M.

Mentalising deficit of people with schizophrenia after recovery
pp. 387-387(1)
Authors: Herold R.; Tenyi T.; Lenard K.; Trixler M.

Reduction of increased striatal dopamine transporter density in adults with attention deficit hyperactivity disorder under methylphenidate - a study with Tc-99m-TRODAT-1-SPECT
pp. 387-388(2)
Authors: Krause J.; Dresel S.; Krause K.-H.; Tatsch K.; Kung H.F.